Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Aliment Pharmacol Ther

Retrieve available abstracts of 505 articles:
HTML format



Single Articles


    July 2022
  1. QUINN KP, Busciglio IA, Burton DD, Inoue A, et al
    Letter: normalizing the ileoanal pouch-more than a one-step technique. Authors' reply.
    Aliment Pharmacol Ther. 2022;56:176-177.
    PubMed    


  2. WEST J, Card TR, Crooks CJ
    Editorial: seeing the light at the end of gastroscope - complications after elective procedures are ready for NICE, bright decision aid tools - authors' reply.
    Aliment Pharmacol Ther. 2022;56:157.
    PubMed    


  3. HADI Y, Kochhar GS
    Letter: paying attention to the comorbidities or extraintestinal complications in patients with inflammatory bowel disease during the COVID-19 pandemic-authors' reply.
    Aliment Pharmacol Ther. 2022;56:178.
    PubMed    


  4. LO SW, Garg M, Segal JP
    Letter: normalising the ileoanal pouch-more than a one-step technique.
    Aliment Pharmacol Ther. 2022;56:174-175.
    PubMed    


  5. BHURWAL A, Mutneja H, Seril D
    Editorial: COVID-19 vaccines are safe and effective in patients with inflammatory bowel disease-but many unanswered questions remain. Authors' reply.
    Aliment Pharmacol Ther. 2022;56:164-165.
    PubMed    


  6. BENCHIMOL EI, Kuenzig ME
    Editorial: COVID-19 vaccines are safe and effective in patients with inflammatory bowel disease-but many unanswered questions remain.
    Aliment Pharmacol Ther. 2022;56:162-163.
    PubMed    


  7. HADI Y, Kochhar GS
    Letter: the effect of anti-COVID-19 treatment on the outcome of patients with inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;56:179.
    PubMed    


  8. FEHILY SR, Al-Ani AH, Abdelmalak J, Rentch C, et al
    Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management.
    Aliment Pharmacol Ther. 2022;56:6-27.
    PubMed     Abstract available


  9. VAUGHAN R, Tjandra D, Patwardhan A, Mingos N, et al
    Toward transmural healing: Sonographic healing is associated with improved long-term outcomes in patients with Crohn's disease.
    Aliment Pharmacol Ther. 2022;56:84-94.
    PubMed     Abstract available


  10. LYONS M, Derikx LAAP, Fulforth J, McCall S, et al
    Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysis.
    Aliment Pharmacol Ther. 2022;56:67-76.
    PubMed     Abstract available


  11. ROBLIN X, Veyrard P, Bastide L, Berger AE, et al
    Subcutaneous injection of infliximab CT-P13 results in stable drug levels within 14-day treatment cycle in Crohn's disease.
    Aliment Pharmacol Ther. 2022;56:77-83.
    PubMed     Abstract available


  12. MASSIRONI S, Vigano C, Danese S
    Letter: pancreatic involvement in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;56:371.
    PubMed    


  13. DAI C, Huang YH
    Letter: pancreatic involvement in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;56:370.
    PubMed    


  14. SOLITANO V, Armuzzi A
    Editorial: STAT3 phosphorylation for tofacitinib monitoring in ulcerative colitis-a step towards precision medicine?
    Aliment Pharmacol Ther. 2022;56:347-348.
    PubMed    


  15. FRIEDMAN S
    Editorial: measuring fertility in men with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;56:345-346.
    PubMed    


  16. GILL M, Majumdar A
    Editorial: optimising hepatitis B vaccine response in inflammatory bowel disease-time to get some skin in the game.
    Aliment Pharmacol Ther. 2022;56:353-354.
    PubMed    


  17. KO KL, Hung IF, Leung WK
    Editorial: optimising hepatitis B vaccine response in inflammatory bowel disease-time to get some skin in the game. Authors' reply.
    Aliment Pharmacol Ther. 2022;56:355-356.
    PubMed    


    June 2022
  18. YUAN WQ, Li F, Yang LC, Yang ZL, et al
    Letter: paying attention to the comorbidities or extraintestinal complications in patients with inflammatory bowel disease during the COVID-19 pandemic.
    Aliment Pharmacol Ther. 2022;55:1464-1465.
    PubMed    


  19. WANG CY, Lai CC
    Letter: the effect of anti-COVID-19 treatment on the outcome of patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;55:1462-1463.
    PubMed    


  20. QUINN KP, Busciglio IA, Burton DD, Inoue A, et al
    Defining normal pouch function in patients with ileal pouch-anal anastomosis: a pilot study.
    Aliment Pharmacol Ther. 2022;55:1560-1568.
    PubMed     Abstract available


    May 2022
  21. SWAMINATHAN A, Fan D, Borichevsky GM, Mules TC, et al
    The disease severity index for inflammatory bowel disease is associated with psychological symptoms, quality of life and predicts a more complicated disease course.
    Aliment Pharmacol Ther. 2022 May 27. doi: 10.1111/apt.17058.
    PubMed     Abstract available


  22. ROSIOU K, Carbonell J, Dolby V, Monfared N, et al
    Sources of excess steroid prescriptions and clinical adverse outcomes associated with steroid excess in patients with inflammatory bowel disease: The Leeds IBD Steroids study.
    Aliment Pharmacol Ther. 2022 May 24. doi: 10.1111/apt.17039.
    PubMed     Abstract available


  23. DRUVEFORS E, Andersson RE, Hammar U, Landerholm K, et al
    Minor impact on fertility in men with inflammatory bowel disease: A National Cohort Study from Sweden.
    Aliment Pharmacol Ther. 2022 May 22. doi: 10.1111/apt.16984.
    PubMed     Abstract available


  24. KO KL, Lam YF, Cheung KS, Hung IF, et al
    Clinical trial: intra-dermal hepatitis B vaccination with topical imiquimod versus intra-muscular hepatitis B vaccination in inflammatory bowel disease patients.
    Aliment Pharmacol Ther. 2022 May 11. doi: 10.1111/apt.16970.
    PubMed     Abstract available


  25. TAXONERA C, Fernandez-Acenero MJ, Olivares D, Calvo M, et al
    Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2022 May 4. doi: 10.1111/apt.16964.
    PubMed     Abstract available


  26. MASSIRONI S, Fanetti I, Vigano C, Pirola L, et al
    Systematic review-Pancreatic involvement in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 May 3. doi: 10.1111/apt.16949.
    PubMed     Abstract available


  27. FALLOON K, Cohen B, Rieder F
    Editorial: shedding new light on extraintestinal manifestations in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;55:1208-1209.
    PubMed    


  28. HADI Y, Kochhar GS
    Letter: association between COVID-19 and inflammatory bowel disease-Authors' reply.
    Aliment Pharmacol Ther. 2022;55:1228-1229.
    PubMed    


  29. KOKKOTIS G, Kitsou K, Bamias G
    Letter: COVID-19 outcomes and anti-TNF treatments-comprehensive evidence matters. Authors' reply.
    Aliment Pharmacol Ther. 2022;55:1235-1236.
    PubMed    


  30. ARDALAN ZS, Friedman AB
    Editorial: the importance of utilising gastrointestinal ultrasound via transperineal approach in ulcerative colitis-an accurate early predictor of response to treatment.
    Aliment Pharmacol Ther. 2022;55:1202-1203.
    PubMed    


  31. GUILLO L, Peyrin-Biroulet L, Danese S
    Editorial: shedding new light on extraintestinal manifestations in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;55:1206-1207.
    PubMed    


  32. BURISCH J, Langholz E, Munkholm P
    Letter: the clinical course of Crohn's disease-the Sicilian experience. Authors' reply.
    Aliment Pharmacol Ther. 2022;55:1239-1240.
    PubMed    


  33. CHEN HY, Wang SI, Chang R, Wei JC, et al
    Letter: association between COVID-19 and inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;55:1226-1227.
    PubMed    


  34. DEMARZO MG, Viola A, Picci A, Fries W, et al
    Letter: the clinical course of Crohn's disease-the Sicilian experience.
    Aliment Pharmacol Ther. 2022;55:1237-1238.
    PubMed    


  35. SAGAMI S, Kobayashi T
    Editorial: the importance of utilising gastrointestinal ultrasound via transperineal approach in ulcerative colitis-an accurate early predictor of response to treatment. Authors' reply.
    Aliment Pharmacol Ther. 2022;55:1204-1205.
    PubMed    


  36. BACHOUR SP, Shah RS, Lyu R, Rieder F, et al
    Mild neoterminal ileal post-operative recurrence of Crohn's disease conveys higher risk for severe endoscopic disease progression than isolated anastomotic lesions.
    Aliment Pharmacol Ther. 2022;55:1139-1150.
    PubMed     Abstract available


  37. WONG ECL, Dulai PS, Marshall JK, Jairath V, et al
    Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn's disease.
    Aliment Pharmacol Ther. 2022;55:1151-1159.
    PubMed     Abstract available


  38. WANG J, Goren I, Rieder F
    Letter: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis-a unique therapeutic target in inflammatory bowel disease. Authors' reply.
    Aliment Pharmacol Ther. 2022;55:1360.
    PubMed    


  39. FERNANDES RG, Radford-Smith G
    Editorial: is older-onset ulcerative colitis more severe or less aggressively managed?
    Aliment Pharmacol Ther. 2022;55:1350-1351.
    PubMed    


  40. RADEKE HH, Stein J
    Letter: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis-a unique therapeutic target in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;55:1359.
    PubMed    


  41. OKABAYASHI S, Yamazaki H, Matsuoka K, Yamamoto Y, et al
    Editorial: is older-onset ulcerative colitis more severe or less aggressively managed? Authors' reply.
    Aliment Pharmacol Ther. 2022;55:1352-1353.
    PubMed    


  42. KUMAR P, Vuyyuru SK, Kedia S, Ahuja V, et al
    Editorial: choosing the optimal screening method for latent TB in patients with IBD commencing anti-TNF-therapy-authors' reply.
    Aliment Pharmacol Ther. 2022;55:1348-1349.
    PubMed    


  43. LOVATT J, Selinger CP
    Editorial: choosing the optimal screening method for latent TB in patients with IBD commencing anti-TNF therapy.
    Aliment Pharmacol Ther. 2022;55:1346-1347.
    PubMed    


    April 2022
  44. VERSTOCKT B, Volk V, Jaeckel C, Alsoud D, et al
    Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2022 Apr 28. doi: 10.1111/apt.16955.
    PubMed     Abstract available


  45. VANDE CASTEELE N, Sandborn WJ, Feagan BG, Vermeire S, et al
    Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study.
    Aliment Pharmacol Ther. 2022 Apr 27. doi: 10.1111/apt.16937.
    PubMed     Abstract available


  46. BERGQVIST V, Holmgren J, Klintman D, Marsal J, et al
    Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Apr 25. doi: 10.1111/apt.16927.
    PubMed     Abstract available


  47. HALFVARSON JF, Ludvigsson JF, Bresso F, Askling J, et al
    Age determines the risk of familial inflammatory bowel disease-A nationwide study.
    Aliment Pharmacol Ther. 2022 Apr 22. doi: 10.1111/apt.16938.
    PubMed     Abstract available


  48. MOENS A, Sadat Seyed Tabib N, Ballet V, Sabino J, et al
    Safety of sequential biological therapy in inflammatory bowel disease: results from a tertiary referral Centre.
    Aliment Pharmacol Ther. 2022 Apr 20. doi: 10.1111/apt.16928.
    PubMed     Abstract available


  49. KHALILI H, Casey K
    Letter: risk of inflammatory bowel disease is related to alcohol consumption as well as ACEIs and ARBs-authors' reply.
    Aliment Pharmacol Ther. 2022;55:884.
    PubMed    


  50. YIN JQ, Wang BQ, Chen ZB, He HD, et al
    Letter: risk of inflammatory bowel disease is related to alcohol consumption as well as ACEIs and ARBs.
    Aliment Pharmacol Ther. 2022;55:882-883.
    PubMed    


  51. MUNGMUNPUNTIPANTIP R, Wiwanitkit V
    Letter: inflammatory bowel disease services during the Covid-19 pandemic.
    Aliment Pharmacol Ther. 2022;55:1063.
    PubMed    


  52. DEPUTY M, Hart A, Faiz O
    Letter: inflammatory bowel disease services during the Covid-19 pandemic - authors' reply.
    Aliment Pharmacol Ther. 2022;55:1064.
    PubMed    


  53. SELINGER CP, Lenti MV, De Silvestri A
    Letter: potential selection bias in real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease-authors' reply.
    Aliment Pharmacol Ther. 2022;55:1070-1071.
    PubMed    


  54. ADOMI M, Ray A
    Letter: potential selection bias in the real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease.
    Aliment Pharmacol Ther. 2022;55:1069.
    PubMed    


  55. KIM ES, Choi S, Choi SY, Park JH, et al
    NUDT15 intermediate metabolisers are associated with lower loss of response in paediatric Crohn's disease patients treated by combination treatment with infliximab and azathioprine.
    Aliment Pharmacol Ther. 2022;55:1008-1015.
    PubMed     Abstract available


  56. ALSOUD D, Verstockt B, Vermeire S
    Letter: immunogenicity is not the root cause for loss of response to anti-TNF agents in patients with IBD in TDM era.
    Aliment Pharmacol Ther. 2022;55:885-886.
    PubMed    


  57. YANG H, Li B, Guo Q, Tang J, et al
    Systematic review with meta-analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2022;55:764-777.
    PubMed     Abstract available


  58. LENTI MV, Dolby V, Clark T, Hall V, et al
    A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study II.
    Aliment Pharmacol Ther. 2022;55:856-866.
    PubMed     Abstract available


    March 2022
  59. BHURWAL A, Mutneja H, Bansal V, Goel A, et al
    Effectiveness and safety of SARS-CoV-2 vaccine in Inflammatory Bowel Disease patients: A systematic review, meta-analysis and meta-regression.
    Aliment Pharmacol Ther. 2022 Mar 30. doi: 10.1111/apt.16913.
    PubMed     Abstract available


  60. TOWNSEND CM, Lovegrove F, Khanna R, Wilson AS, et al
    Review article: paradoxical psoriasis as a consequence of tumour necrosis factor antagonists in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Mar 21. doi: 10.1111/apt.16883.
    PubMed     Abstract available


  61. ZAMANI M, Alizadeh-Tabari S, Singh S, Loomba R, et al
    Meta-analysis: Prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Mar 11. doi: 10.1111/apt.16879.
    PubMed     Abstract available


  62. OKABAYASHI S, Yamazaki H, Tominaga K, Miura M, et al
    Lower effectiveness of intravenous steroid treatment for moderate-to-severe ulcerative colitis in hospitalised patients with older onset: A multicentre cohort study.
    Aliment Pharmacol Ther. 2022 Mar 11. doi: 10.1111/apt.16865.
    PubMed     Abstract available


  63. FALLOON K, Cohen B, Ananthakrishnan AN, Barnes EL, et al
    A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Mar 11. doi: 10.1111/apt.16853.
    PubMed     Abstract available


  64. SINGH AK, Jena A, Mahajan G, Mohindra R, et al
    Meta-analysis: Hepatitis B vaccination in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Mar 8. doi: 10.1111/apt.16880.
    PubMed     Abstract available


  65. SUNG KY, Zhang B, Wang HE, Bai YM, et al
    Schizophrenia and risk of new-onset inflammatory bowel disease: a nationwide longitudinal study.
    Aliment Pharmacol Ther. 2022 Mar 8. doi: 10.1111/apt.16856.
    PubMed     Abstract available


  66. PANACCIONE R, Abreu MT, Lazariciu I, Mundayat R, et al
    Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: Data from the open-label, long-term extension study, OCTAVE open.
    Aliment Pharmacol Ther. 2022 Mar 5. doi: 10.1111/apt.16848.
    PubMed    


  67. JAYASOORIYA N, Blackwell J, Saxena S, Bottle A, et al
    Antidepressant medication use in Inflammatory Bowel Disease: a nationally representative population-based study.
    Aliment Pharmacol Ther. 2022 Mar 4. doi: 10.1111/apt.16820.
    PubMed     Abstract available


  68. SAVELKOUL EHJ, Hoentjen F
    Editorial: anti-TNF combination therapy for inflammatory bowel disease-one size does not fit all.
    Aliment Pharmacol Ther. 2022;55:750-751.
    PubMed    


  69. HONAP S, Dart RJ, Samaan MA
    Editorial: protecting hypoxia-inducible factor-1alpha and gut integrity with GB004-a promising therapeutic approach for ulcerative colitis?
    Aliment Pharmacol Ther. 2022;55:733-734.
    PubMed    


  70. DANESE S, Levesque BG, Feagan BG, Jucov A, et al
    Editorial: protecting hypoxia-inducible factor 1a and gut integrity with GB004-a promising therapeutic approach for ulcerative colitis? Authors' reply.
    Aliment Pharmacol Ther. 2022;55:735-736.
    PubMed    


  71. KUMAR P, Vuyyuru SK, Kante B, Sahu P, et al
    Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti-TNF therapy in tuberculosis endemic region.
    Aliment Pharmacol Ther. 2022 Mar 1. doi: 10.1111/apt.16839.
    PubMed     Abstract available


  72. ZHAO M, Sall Jensen M, Knudsen T, Kelsen J, et al
    Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases - a Danish nationwide cohort study.
    Aliment Pharmacol Ther. 2022;55:541-557.
    PubMed     Abstract available


  73. COLMAN RJ, Xiong Y, Mizuno T, Hyams JS, et al
    Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2022;55:593-603.
    PubMed     Abstract available


  74. COHEN NA, Pekow J
    Editorial: time to modify practice and use the modified Rutgeert's score.
    Aliment Pharmacol Ther. 2022;55:754-755.
    PubMed    


  75. BANERJEE R, Raghunathan N
    Editorial: a paradigm shift in NUDT15 assessment-towards predictive and personalised medicine in Crohn's disease?
    Aliment Pharmacol Ther. 2022;55:740-741.
    PubMed    


  76. KIM ES, Kang B
    Editorial: a paradigm shift in NUDT15 assessment-towards predictive and personalised medicine in Crohn's disease? Authors' reply.
    Aliment Pharmacol Ther. 2022;55:742-743.
    PubMed    


    February 2022
  77. BALLESTER MP, Mesonero F, Florez-Diez P, Gomez C, et al
    Adherence to endoscopic surveillance for advanced lesions and colorectal cancer in inflammatory bowel disease: an AEG and GETECCU collaborative cohort study.
    Aliment Pharmacol Ther. 2022 Feb 27. doi: 10.1111/apt.16832.
    PubMed     Abstract available


  78. SAGAMI S, Kobayashi T, Aihara K, Umeda M, et al
    Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis.
    Aliment Pharmacol Ther. 2022 Feb 25. doi: 10.1111/apt.16817.
    PubMed     Abstract available


  79. YE Z, Qian L, Hu W, Miao S, et al
    Clinical outcome of infantile-onset inflammatory bowel disease in 102 patients with interleukin-10 signalling deficiency.
    Aliment Pharmacol Ther. 2022 Feb 20. doi: 10.1111/apt.16837.
    PubMed     Abstract available


  80. GROSSBERG LB, Papamichael K, Cheifetz AS
    Review: emerging drug therapies in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Feb 15. doi: 10.1111/apt.16785.
    PubMed     Abstract available


  81. WAN J, Wang X, Zhang Y, Chen M, et al
    Systematic review and meta-analysis: incidence and factors for progression to advanced neoplasia in inflammatory bowel disease patients with indefinite and low-grade dysplasia.
    Aliment Pharmacol Ther. 2022 Feb 15. doi: 10.1111/apt.16789.
    PubMed     Abstract available


  82. DEPUTY M, Sahnan K, Worley G, Patel K, et al
    The use of, and outcomes for, inflammatory bowel disease services during the Covid-19 pandemic: a nationwide observational study.
    Aliment Pharmacol Ther. 2022 Feb 7. doi: 10.1111/apt.16800.
    PubMed     Abstract available


  83. SCHREIBER S, Irving PM, Sharara AI, Martin-Arranz MD, et al
    Review: randomised controlled trials in inflammatory bowel disease-common challenges and potential solutions.
    Aliment Pharmacol Ther. 2022 Feb 7. doi: 10.1111/apt.16781.
    PubMed     Abstract available


  84. POLLOK RCG, Jayasooriya N
    Editorial: early and persistent biological treatment and its impact on long term surgical outcomes in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;55:370-371.
    PubMed    


  85. TAXONERA C
    Editorial: real-world safety of tofacitinib in ulcerative colitis.
    Aliment Pharmacol Ther. 2022;55:368-369.
    PubMed    


  86. MAHMOUD R, Schultheiss JPD, Fidder HH, Oldenburg B, et al
    Letter: loss of response to anti-TNFalpha agents depends on treatment duration in patients with inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;55:499-500.
    PubMed    


  87. BEN-HORIN S, Ungar B
    Letter: loss of response to anti-TNFalpha agents in patients with inflammatory bowel disease depends on treatment duration.
    Aliment Pharmacol Ther. 2022;55:497-498.
    PubMed    


  88. GOODSALL TM, Bryant RV
    Editorial: an accurate, reliable and responsive ultrasound activity score for Crohn's disease? Sounds good to US.
    Aliment Pharmacol Ther. 2022;55:360-361.
    PubMed    


  89. ALLOCCA M, Danese S
    Editorial: an accurate, reliable and responsive ultrasound activity score for Crohn's disease? Sounds good to US. Authors' reply.
    Aliment Pharmacol Ther. 2022;55:362-363.
    PubMed    


  90. ALLOCCA M, Craviotto V, Dell'Avalle C, Furfaro F, et al
    Bowel ultrasound score is accurate in assessing response to therapy in patients with Crohn's disease.
    Aliment Pharmacol Ther. 2022;55:446-454.
    PubMed     Abstract available


  91. SKEJO C, Vestergaard T, Julsgaard M
    Editorial: safety of ustekinumab in pregnancy-are we there yet?
    Aliment Pharmacol Ther. 2022;55:495-496.
    PubMed    


  92. CARON B, Fumery M, Netter P, Peyrin-Biroulet L, et al
    Letter: treatment with subcutaneous CT-P13 in Crohn's disease patients with intravenous infliximab failure.
    Aliment Pharmacol Ther. 2022;55:508-509.
    PubMed    


  93. PARROT L, Dong C, Carbonnel F, Meyer A, et al
    Systematic review with meta-analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor.
    Aliment Pharmacol Ther. 2022;55:380-388.
    PubMed     Abstract available


    January 2022
  94. THOMSEN SB, Ungaro RC, Allin KH, Elmahdi R, et al
    Impact of thiopurine discontinuation at anti-tumour necrosis factor initiation in inflammatory bowel disease treatment: a nationwide Danish cohort study.
    Aliment Pharmacol Ther. 2022 Jan 25. doi: 10.1111/apt.16777.
    PubMed     Abstract available


  95. DANESE S, Levesque BG, Feagan BG, Jucov A, et al
    Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1alpha stabiliser, for treatment of ulcerative colitis.
    Aliment Pharmacol Ther. 2022 Jan 10. doi: 10.1111/apt.16753.
    PubMed     Abstract available


  96. VEISMAN I, Ben-Horin S
    Editorial: tofacitinib post-marketing safety reports among ulcerative colitis patients.
    Aliment Pharmacol Ther. 2022;55:131-132.
    PubMed    


  97. LAHARIE D, Riviere P
    Editorial: don't forget basic performance measures in the endoscopic assessment of ulcerative colitis.
    Aliment Pharmacol Ther. 2022;55:129-130.
    PubMed    


  98. CARBONNEL F, Meyer A
    Editorial: subcutaneous CT-P13 in Crohn's disease and ulcerative colitis-small change, big consequences.
    Aliment Pharmacol Ther. 2022;55:251-252.
    PubMed    


  99. GOREN I, Yanai H
    Editorial: risk of loss of response to anti-TNFalpha agents in patients with inflammatory bowel disease-the longer the less?
    Aliment Pharmacol Ther. 2022;55:244-245.
    PubMed    


  100. HANZEL J, Bukkems LH, Gecse KB, D'Haens GR, et al
    Editorial: subcutaneous CT-P13 in Crohn's disease and ulcerative colitis-small change, big consequences. Authors' reply.
    Aliment Pharmacol Ther. 2022;55:253-254.
    PubMed    


  101. VASUDEVAN A, van Langenberg DR
    Editorial: delving into the natural history of Crohn's disease and the impact of medical therapy.
    Aliment Pharmacol Ther. 2022;55:108-109.
    PubMed    


  102. BURISCH J, Langholz E, Munkholm P
    Editorial: delving into the natural history of Crohn's disease and the impact of medical therapy-authors' reply.
    Aliment Pharmacol Ther. 2022;55:110-111.
    PubMed    


  103. KHAN N, Patel D, Trivedi C, Pernes T, et al
    The impact of IBD medications on risk of pneumonia and pneumonia-related hospitalisation: a nationwide cohort study of 56 410 IBD patients.
    Aliment Pharmacol Ther. 2022;55:64-72.
    PubMed     Abstract available


  104. BURISCH J, Lophaven S, Langholz E, Munkholm P, et al
    The clinical course of Crohn's disease in a Danish population-based inception cohort with more than 50 years of follow-up, 1962-2017.
    Aliment Pharmacol Ther. 2022;55:73-82.
    PubMed     Abstract available


  105. REZAZADEH ARDABILI A, Mujagic Z, Jonkers DMAE, Pierik MJ, et al
    Letter: screening for infectious side effects in patients with IBD-the importance and potential of real-world remote monitoring.
    Aliment Pharmacol Ther. 2022;55:260-261.
    PubMed    


  106. SCHULTHEISS JPD, Mahmoud R, Fidder HH, Oldenburg B, et al
    Editorial: risk of loss of response to anti TNFalpha in patients with inflammatory bowel diseases - the longer the less? Authors' reply.
    Aliment Pharmacol Ther. 2022;55:246.
    PubMed    


  107. KHAN N, Yang YX
    Letter: screening for infectious side effects in patients with IBD-the importance and potential of real-world remote monitoring. Authors' reply.
    Aliment Pharmacol Ther. 2022;55:262.
    PubMed    


  108. MA C, MacDonald JK, Nguyen TM, Chang J, et al
    Systematic review: disease activity indices for immune checkpoint inhibitor-associated enterocolitis.
    Aliment Pharmacol Ther. 2022;55:178-190.
    PubMed     Abstract available


    December 2021
  109. WANG J, Goren I, Yang B, Lin S, et al
    The sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis: a unique therapeutic target in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Dec 21. doi: 10.1111/apt.16741.
    PubMed     Abstract available


  110. FLANAGAN E, Prentice R, Wright EK, Gibson PR, et al
    Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero.
    Aliment Pharmacol Ther. 2021 Dec 14. doi: 10.1111/apt.16739.
    PubMed     Abstract available


  111. FORSS A, Clements M, Bergman D, Roelstraete B, et al
    A nationwide cohort study of the incidence of inflammatory bowel disease in Sweden from 1990 to 2014.
    Aliment Pharmacol Ther. 2021 Dec 14. doi: 10.1111/apt.16735.
    PubMed     Abstract available


  112. HADI Y, Dulai PS, Kupec J, Mohy-Ud-Din N, et al
    Incidence, outcomes, and impact of COVID-19 on inflammatory bowel disease: Propensity matched research network analysis.
    Aliment Pharmacol Ther. 2021 Dec 14. doi: 10.1111/apt.16730.
    PubMed     Abstract available


  113. CASEY K, Lopes EW, Niccum B, Burke K, et al
    Alcohol consumption and risk of inflammatory bowel disease among three prospective US cohorts.
    Aliment Pharmacol Ther. 2021 Dec 8. doi: 10.1111/apt.16731.
    PubMed     Abstract available


  114. MESERVE J, Singh S
    Editorial: risk of pneumonia in IBD-reading between the lines!
    Aliment Pharmacol Ther. 2021;54.
    PubMed    


  115. HAMDEH S, Micic D, Hanauer S
    Review article: drug-induced small bowel injury.
    Aliment Pharmacol Ther. 2021;54.
    PubMed     Abstract available


  116. SANDBORN WJ, Lawendy N, Danese S, Su C, et al
    Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment.
    Aliment Pharmacol Ther. 2021 Dec 1. doi: 10.1111/apt.16712.
    PubMed     Abstract available


    November 2021
  117. ZHAO M, Feng R, Ben-Horin S, Zhuang X, et al
    Systematic review with meta-analysis: environmental and dietary differences of inflammatory bowel disease in Eastern and Western populations.
    Aliment Pharmacol Ther. 2021 Nov 24. doi: 10.1111/apt.16703.
    PubMed     Abstract available


  118. RADHAKRISHNAN ST, Alexander JL, Mullish BH, Gallagher KI, et al
    Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Nov 9. doi: 10.1111/apt.16656.
    PubMed     Abstract available


  119. CHAO K, Huang Y, Zhu X, Tang J, et al
    Randomised clinical trial: dose optimising strategy by NUDT15 genotyping reduces leucopenia during thiopurine treatment of Crohn's disease.
    Aliment Pharmacol Ther. 2021;54:1124-1133.
    PubMed     Abstract available


    October 2021
  120. BURISCH J, Lophaven S, Munkholm P, Langholz E, et al
    Surgery, cancer and mortality among patients with ulcerative colitis diagnosed 1962-1987 and followed until 2017 in a Danish population-based inception cohort.
    Aliment Pharmacol Ther. 2021 Oct 29. doi: 10.1111/apt.16677.
    PubMed     Abstract available


  121. BEZZIO C, Armuzzi A, Furfaro F, Ardizzone S, et al
    Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.
    Aliment Pharmacol Ther. 2021 Oct 25. doi: 10.1111/apt.16663.
    PubMed     Abstract available


  122. PASVOL TJ, Bloom S, Segal AW, Rait G, et al
    Use of contraceptives and risk of inflammatory bowel disease: A nested case-control study.
    Aliment Pharmacol Ther. 2021 Oct 18. doi: 10.1111/apt.16647.
    PubMed     Abstract available


  123. RUBIN DT, Modesto I, Vermeire S, Danese S, et al
    Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis.
    Aliment Pharmacol Ther. 2021 Oct 9. doi: 10.1111/apt.16619.
    PubMed     Abstract available


  124. FEAGAN BG, Khanna R, Sandborn WJ, Vermeire S, et al
    Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials.
    Aliment Pharmacol Ther. 2021 Oct 6. doi: 10.1111/apt.16626.
    PubMed     Abstract available


  125. TAKENAKA K, Kawamoto A, Ohtsuka K
    Editorial: higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease-authors' reply.
    Aliment Pharmacol Ther. 2021;54:1087.
    PubMed    


  126. RAKOWSKY S, Cheifetz AS, Papamichael K
    Editorial: higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease.
    Aliment Pharmacol Ther. 2021;54:1085-1086.
    PubMed    


  127. JOLVING LR, Anru PL, Nielsen J, Friedman S, et al
    The risk of chronic diseases and congenital malformations during childhood and adolescence after in utero exposure to thiopurines.
    Aliment Pharmacol Ther. 2021;54:1061-1069.
    PubMed     Abstract available


  128. SAINZ E, Zabana Y, Miguel I, Fernandez-Clotet A, et al
    Clinical features, therapeutic requirements and evolution of patients with Crohn's disease and upper gastrointestinal involvement (CROHNEX study).
    Aliment Pharmacol Ther. 2021;54:1041-1051.
    PubMed     Abstract available


  129. TAKENAKA K, Kawamoto A, Hibiya S, Suzuki K, et al
    Higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease.
    Aliment Pharmacol Ther. 2021;54:1052-1060.
    PubMed     Abstract available


    September 2021
  130. MULES TC, Swaminathan A, Hirschfeld E, Borichevsky G, et al
    The impact of disease activity on psychological symptoms and quality of life in patients with inflammatory bowel disease-results from the Stress, Anxiety and Depression with Disease Activity (SADD) Study.
    Aliment Pharmacol Ther. 2021 Sep 29. doi: 10.1111/apt.16616.
    PubMed     Abstract available


  131. SCHULTHEISS JPD, Mahmoud R, Louwers JM, van der Kaaij MT, et al
    Loss of response to anti-TNFalpha agents depends on treatment duration in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Sep 24. doi: 10.1111/apt.16605.
    PubMed     Abstract available


  132. HANZEL J, Bukkems LH, Gecse KB, D'Haens GR, et al
    Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn's disease and ulcerative colitis.
    Aliment Pharmacol Ther. 2021 Sep 24. doi: 10.1111/apt.16609.
    PubMed     Abstract available


  133. DOHERTY J, Fennessy S, Stack R, O' Morain N, et al
    Review Article: Vaccination for patients with inflammatory bowel disease during the COVID-19 pandemic.
    Aliment Pharmacol Ther. 2021 Sep 2. doi: 10.1111/apt.16590.
    PubMed     Abstract available


  134. SAITTA D, Garg M
    Letter: missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel disease-still significant room for improvement.
    Aliment Pharmacol Ther. 2021;54:734-735.
    PubMed    


  135. BLESL A, Hogenauer C, Borenich A, Berghold A, et al
    Editorial: does anti-TNF 'treatment persistence' always equate to 'effective treatment'? Only objective disease assessments can answer the question. Authors' reply.
    Aliment Pharmacol Ther. 2021;54:720-721.
    PubMed    


  136. BLESL A, Binder L, Hogenauer C, Wenzl H, et al
    Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study.
    Aliment Pharmacol Ther. 2021;54:667-677.
    PubMed     Abstract available


  137. VISURI I, Eriksson C, Olen O, Cao Y, et al
    Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence-authors' reply.
    Aliment Pharmacol Ther. 2021;54:848-849.
    PubMed    


  138. VEYRARD P, Nancey S, Roblin X
    Editorial: 5-ASA in IBD patients on biologics-'stop or continue'?
    Aliment Pharmacol Ther. 2021;54:843-844.
    PubMed    


  139. BERNSTEIN CN, Tennakoon A, Singh H, Targownik L, et al
    Editorial: 5-ASA in IBD patients on biologics-'stop or continue'? Authors' reply.
    Aliment Pharmacol Ther. 2021;54:845.
    PubMed    


  140. HAYDEK JP, Scott FI
    Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence.
    Aliment Pharmacol Ther. 2021;54:846-847.
    PubMed    


  141. PIERRE N, Salee C, Vieujean S, Bequet E, et al
    Review article: distinctions between ileal and colonic Crohn's disease: from physiology to pathology.
    Aliment Pharmacol Ther. 2021;54:779-791.
    PubMed     Abstract available


  142. BERNSTEIN CN, Tenakoon A, Singh H, Targownik LE, et al
    Continued 5ASA use after initiation of anti-TNF or immunomodulator confers no benefit in IBD: a population-based study.
    Aliment Pharmacol Ther. 2021;54:814-832.
    PubMed     Abstract available


    August 2021
  143. SLEUTJES JAM, Roeters van Lennep JE, Boersma E, Menchen LA, et al
    Systematic review with meta-analysis: effect of inflammatory bowel disease therapy on lipid levels.
    Aliment Pharmacol Ther. 2021 Aug 28. doi: 10.1111/apt.16580.
    PubMed     Abstract available


  144. HONAP S, Pavlidis P, Irving PM
    Editorial: is tofacitinib another rescue option for acute severe ulcerative colitis?
    Aliment Pharmacol Ther. 2021;54:341-342.
    PubMed    


  145. BIEMANS VBC, Straatmijer T, Hoentjen F, Pierik MJ, et al
    Letter: tofacitinib in treatment-refractory ulcerative colitis-a single centre real-world experience in Australia. Authors' reply.
    Aliment Pharmacol Ther. 2021;54:534-535.
    PubMed    


  146. LO SW, Connell W, Kamm MA, Lust M, et al
    Letter: tofacitinib in biologic-experienced ulcerative colitis-a single-centre real-world experience in Australia.
    Aliment Pharmacol Ther. 2021;54:532-533.
    PubMed    


  147. ROBLIN X, Nancey S, Paul S
    Letter: predicting treatment discontinuation in inflammatory bowel disease-anti-TNF trough levels and anti-drug antibodies. Authors' reply.
    Aliment Pharmacol Ther. 2021;54:538-539.
    PubMed    


  148. FRIEDMAN AB, Gibson PR
    Editorial: assessment of inflammatory bowel disease: a picture is worth a thousand words. Authors' reply.
    Aliment Pharmacol Ther. 2021;54:510.
    PubMed    


  149. HORJUS-TALABUR HORJE CS, van Bodegraven AA
    Editorial: assessment of inflammatory bowel disease-a picture is worth a thousand words.
    Aliment Pharmacol Ther. 2021;54:508-509.
    PubMed    


  150. TSOI AH, Murugasu A, Garg M
    Letter: assessment of histological disease activity in Crohn's disease clinical trials-a step in the right direction, but further optimisation needed.
    Aliment Pharmacol Ther. 2021;54:541-542.
    PubMed    


  151. DEMARZO MG, Bodini G, Giuliana E, Zentilin P, et al
    Letter: predictive factors for treatment discontinuation in IBD-anti-TNF trough levels and anti-drug antibodies.
    Aliment Pharmacol Ther. 2021;54:536-537.
    PubMed    


  152. MATTOO VY, Basnayake C, Connell WR, Ding N, et al
    Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn's disease.
    Aliment Pharmacol Ther. 2021;54:249-266.
    PubMed     Abstract available


    July 2021
  153. LAMBERT K, Pappas D, Miglioretto C, Javadpour A, et al
    Systematic review with meta-analysis: dietary intake in adults with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Jul 29. doi: 10.1111/apt.16549.
    PubMed     Abstract available


  154. FUMERY M, Filippi J, Abitbol V, Biron A, et al
    Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study.
    Aliment Pharmacol Ther. 2021 Jul 23. doi: 10.1111/apt.16544.
    PubMed     Abstract available


  155. VISURI I, Eriksson C, Olen O, Cao Y, et al
    Predictors of drug survival: A cohort study comparing anti-tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register.
    Aliment Pharmacol Ther. 2021 Jul 19. doi: 10.1111/apt.16525.
    PubMed     Abstract available


  156. MCGING JJ, Radford SJ, Francis ST, Serres S, et al
    Review article: The aetiology of fatigue in inflammatory bowel disease and potential therapeutic management strategies.
    Aliment Pharmacol Ther. 2021 Jul 6. doi: 10.1111/apt.16465.
    PubMed     Abstract available


  157. LUBER RP, O'Neill R, Singh S, Sharma E, et al
    An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch.
    Aliment Pharmacol Ther. 2021 Jul 5. doi: 10.1111/apt.16497.
    PubMed     Abstract available


  158. ROTONDO-TRIVETTE S, Wang B, Gayer C, Parsana R, et al
    Decreased secondary faecal bile acids in children with ulcerative colitis and Clostridioides difficile infection.
    Aliment Pharmacol Ther. 2021 Jul 4. doi: 10.1111/apt.16496.
    PubMed     Abstract available


  159. OSENI E, Sultan K
    Letter: opioid use, early biologic discontinuation for inflammatory bowel disease and a cautionary note for the age of legalised cannabis.
    Aliment Pharmacol Ther. 2021;54:92-93.
    PubMed    


  160. JORDI SBU, Misselwitz B, Begre S
    Editorial: type D personality and its relationship with depression and disease activity in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2021;54:82-83.
    PubMed    


  161. KNOWLES SR, Mikocka-Walus A
    Editorial: type D personality and its relationship with depression and disease activity in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021;54:80-81.
    PubMed    


  162. FAN D, Gearry RB
    Editorial: IBD medications during the COVID-19 pandemic-are they safe to use?
    Aliment Pharmacol Ther. 2021;54:208-209.
    PubMed    


  163. TASSONE D, Singh S, Sheng Ding N
    Editorial: impact of body mass index on clinical outcomes in patients with ulcerative colitis treated with tofacitinib.
    Aliment Pharmacol Ther. 2021;54:206-207.
    PubMed    


  164. MEYER A, Semenzato L, Zureik M, Weill A, et al
    Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study.
    Aliment Pharmacol Ther. 2021;54:160-166.
    PubMed     Abstract available


  165. CASANOVA MJ, Chaparro M, Gisbert JP
    Editorial: withdrawal of anti-TNFalpha-are we ready for biological therapy cycling? Authors' reply.
    Aliment Pharmacol Ther. 2021;54:86-87.
    PubMed    


  166. PUGLIESE D, Armuzzi A
    Editorial: withdrawal of anti TNF-alpha - are we ready for biological therapy cycling?
    Aliment Pharmacol Ther. 2021;54:84-85.
    PubMed    


  167. WEISSHOF R, Chowers Y, Kurnik D
    Editorial: safety of thiopurines in pregnancy-considering the mother, foetus and newborn.
    Aliment Pharmacol Ther. 2021;54:88-89.
    PubMed    


    June 2021
  168. FARRAYE FA, Qazi T, Kotze PG, Moore GT, et al
    The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme.
    Aliment Pharmacol Ther. 2021 Jun 24. doi: 10.1111/apt.16439.
    PubMed     Abstract available


  169. MEYER A, Drouin J, Weill A, Carbonnel F, et al
    Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti-TNF: a French nationwide study 2010-2018.
    Aliment Pharmacol Ther. 2021 Jun 23. doi: 10.1111/apt.16448.
    PubMed     Abstract available


  170. FRIEDMAN AB, Asthana A, Knowles SR, Robbins A, et al
    Effect of point-of-care gastrointestinal ultrasound on decision-making and management in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Jun 22. doi: 10.1111/apt.16452.
    PubMed     Abstract available


  171. BERNSTEIN CN, Nugent Z, Shaffer S, Singh H, et al
    Comorbidity before and after a diagnosis of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Jun 22. doi: 10.1111/apt.16444.
    PubMed     Abstract available


  172. UZZAN M, Bresteau C, Laharie D, Stefanescu C, et al
    Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort.
    Aliment Pharmacol Ther. 2021 Jun 20. doi: 10.1111/apt.16463.
    PubMed     Abstract available


  173. KO Y, Paramsothy S, Yau Y, Leong RW, et al
    Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
    Aliment Pharmacol Ther. 2021 Jun 20. doi: 10.1111/apt.16436.
    PubMed     Abstract available


  174. VAN LINSCHOTEN RCA, Visser E, Niehot CD, van der Woude CJ, et al
    Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents.
    Aliment Pharmacol Ther. 2021 Jun 11. doi: 10.1111/apt.16445.
    PubMed     Abstract available


  175. FAIRBRASS KM, Gracie DJ, Ford AC
    Longitudinal follow-up study: effect of psychological co-morbidity on the prognosis of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Jun 11. doi: 10.1111/apt.16454.
    PubMed     Abstract available


  176. LAMB CA, Sebastian S, Kent AJ, Segal JP, et al
    Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study.
    Aliment Pharmacol Ther. 2021;53:1236-1240.
    PubMed    


  177. EL-MATARY W, Nugent Z, Witt J, Bernstein CN, et al
    Editorial: trends in paediatric inflammatory bowel disease attributable direct costs-authors' reply.
    Aliment Pharmacol Ther. 2021;53:1234-1235.
    PubMed    


  178. VERNON-ROBERTS A, Day AS
    Editorial: trends in paediatric inflammatory bowel disease attributable direct costs.
    Aliment Pharmacol Ther. 2021;53:1232-1233.
    PubMed    


  179. TANNOURY J, Amiot A
    Editorial: determining disability in inflammatory bowel disease-"See(k) and you shall find". Authors' reply.
    Aliment Pharmacol Ther. 2021;53:1323.
    PubMed    


  180. TURBAYNE AKB, Ward MG
    Editorial: total anti-drug antibodies detected using drug-tolerant assays during induction with anti-TNF therapy are associated with treatment failure-out of sight but not out of mind.
    Aliment Pharmacol Ther. 2021;53:1317-1318.
    PubMed    


  181. ROBLIN X, Nancey S, Paul S
    Editorial: total anti-drug antibodies detected using drug-tolerant assays during induction with anti-TNF therapy are associated with treatment failure-out of sight but not out of mind. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:1319-1320.
    PubMed    


  182. LIMDI JK
    Editorial: determining disability in IBD - 'See(k) and you shall find'.
    Aliment Pharmacol Ther. 2021;53:1321-1322.
    PubMed    


  183. MANLAY L, Boschetti G, Pereira B, Flourie B, et al
    Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.
    Aliment Pharmacol Ther. 2021;53:1289-1299.
    PubMed     Abstract available


    May 2021
  184. JORDI SBU, Botte F, Lang BM, Greuter T, et al
    Type D personality is associated with depressive symptoms and clinical activity in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 May 11. doi: 10.1111/apt.16365.
    PubMed     Abstract available


  185. CASANOVA MJ, Chaparro M, Nantes O, Benitez JM, et al
    Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study.
    Aliment Pharmacol Ther. 2021 May 7. doi: 10.1111/apt.16361.
    PubMed     Abstract available


  186. SRINIVASAN A, Haifer C, Thin L
    Editorial: outcomes following a second switch-evaluating clinical outcomes and patient perspectives in IBD.
    Aliment Pharmacol Ther. 2021;53:1038-1039.
    PubMed    


  187. WILSON A, Kim RB
    Letter: genetic variation in the HLA-DQA1*05 allele predicts tumour necrosis factor-alpha antagonist immunogenicity - does location matter?
    Aliment Pharmacol Ther. 2021;53:1055-1056.
    PubMed    


  188. DEMARZO MG, Bodini G, Vanello M, Martini M, et al
    Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD.
    Aliment Pharmacol Ther. 2021;53:1044-1045.
    PubMed    


  189. RUNDQUIST S, Sachs MC, Eriksson C, Olen O, et al
    Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:1046-1047.
    PubMed    


  190. MESONERO F, Castro-Poceiro J, Benitez JM, Camps B, et al
    Effectiveness and safety of methotrexate monotherapy in patients with Crohn's disease refractory to anti-TNF-alpha: results from the ENEIDA registry.
    Aliment Pharmacol Ther. 2021;53:1021-1029.
    PubMed     Abstract available


  191. SEDANO R, Ma C, Jairath V
    Editorial: standardising inclusion and outcome criteria for pouchitis-a fragile consensus perhaps but a first step in the right direction. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:1149-1150.
    PubMed    


  192. LAUBE R, Selinger CP
    Editorial: standardising inclusion and outcome criteria for pouchitis-a fragile consensus perhaps but a first step in the right direction.
    Aliment Pharmacol Ther. 2021;53:1147-1148.
    PubMed    


  193. TANNOURY J, Nachury M, Martins C, Serrero M, et al
    Determinants of IBD-related disability: a cross-sectional survey from the GETAID.
    Aliment Pharmacol Ther. 2021;53:1098-1107.
    PubMed     Abstract available


  194. TJANDRA D, Garg M, Behrenbruch C, McCormick J, et al
    Review article: investigation and management of internal fistulae in Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:1064-1079.
    PubMed     Abstract available


    April 2021
  195. DHALIWAL J, McKay HE, Deslandres C, Debruyn J, et al
    One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study.
    Aliment Pharmacol Ther. 2021 Apr 28. doi: 10.1111/apt.16388.
    PubMed     Abstract available


  196. TOURNIER Q, Paul S, Williet N, Berger AE, et al
    Early detection of anti-drug antibodies during initiation of anti-tumour necrosis factor therapy predicts treatment discontinuation in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Apr 19. doi: 10.1111/apt.16333.
    PubMed     Abstract available


  197. EL-MATARY W, Nugent Z, Witt J, Bernstein CN, et al
    Trends in paediatric inflammatory bowel disease-attributable direct costs: a population-based analysis.
    Aliment Pharmacol Ther. 2021 Apr 9. doi: 10.1111/apt.16358.
    PubMed     Abstract available


  198. VAN DER HAVE M, Maljaars J
    Editorial: opioids in inflammatory bowel disease-primum non nocere.
    Aliment Pharmacol Ther. 2021;53:844-845.
    PubMed    


  199. RHUDY C, Perry CL, Barrett TA
    Editorial: opioids in inflammatory bowel disease-primum non nocere. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:846.
    PubMed    


  200. JANGI S, Yoon H, Dulai P, Valasek M, et al
    Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitis-authors' reply.
    Aliment Pharmacol Ther. 2021;53:957-958.
    PubMed    


  201. MAEDA Y, Kudo SE, Takishima K, Misawa M, et al
    Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitis.
    Aliment Pharmacol Ther. 2021;53:955-956.
    PubMed    


  202. PRENTICE RE, Hollingsworth L, Middleton C, Wilson J, et al
    Letter: colorectal cancer surveillance in inflammatory bowel disease-a call for systematic reform.
    Aliment Pharmacol Ther. 2021;53:953-954.
    PubMed    


  203. LUBELL JM
    Letter: future studies of high-dose thiamine should consider whether its effects on fatigue are related to the inhibition of carbonic anhydrase isoenzymes.
    Aliment Pharmacol Ther. 2021;53:851-852.
    PubMed    


  204. BAGER P, Hvas C, Rud C, Dahlerup J, et al
    Letter: future studies of high-dose thiamine should consider whether its effects on fatigue are related to the inhibition of carbonic anhydrase isoenzymes. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:853-854.
    PubMed    


  205. LIM G, Kassam Z, Seow CH
    Letter: is the radiation therapy causing an IBD flare, or the IBD predisposing to radiation toxicity?
    Aliment Pharmacol Ther. 2021;53:855-856.
    PubMed    


  206. TURSI A, Mocci G, Picchio M, Elisei W, et al
    Letter: ustekinumab for the treatment of post-surgical and refractory Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:859-860.
    PubMed    


  207. LAHARIE D, Riviere P
    Letter: is the radiation therapy causing an IBD flare, or the IBD predisposing to radiation toxicity? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:857-858.
    PubMed    


  208. ALMRADI A, Ma C, D'Haens GR, Sandborn WJ, et al
    An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials.
    Aliment Pharmacol Ther. 2021;53:784-793.
    PubMed     Abstract available


  209. ABUSHAMMA S, Deepak P
    Editorial: use of intestinal ultrasound in the scoring of Crohn's disease activity in clinical trials-is it ready for prime time yet?
    Aliment Pharmacol Ther. 2021;53:946-947.
    PubMed    


  210. JAIRATH V, Almradi A, Pai RK, Ma C, et al
    Editorial: an expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials-a missing link. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:952.
    PubMed    


  211. TANDON P, Narula N
    Editorial: methotrexate in patients with Crohn's disease refractory to anti-TNF therapy-moving backwards yet forward?
    Aliment Pharmacol Ther. 2021;53:950-951.
    PubMed    


  212. GOODSALL TM, Jairath V, Bryant RV, Ma C, et al
    Editorial: use of intestinal ultrasound in the scoring of Crohn's disease activity in clinical trials - is it ready for prime time yet? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:948-949.
    PubMed    


  213. GOODSALL TM, Jairath V, Feagan BG, Parker CE, et al
    Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:873-886.
    PubMed     Abstract available


    March 2021
  214. WORLEY G, Faiz O
    Editorial: time trends in colectomy rates for ulcerative colitis in England-mixed methods brings mixed messages? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:661-662.
    PubMed    


  215. BODGER K
    Editorial: time trends in colectomy rates for ulcerative colitis in England-mixed methods brings mixed messages?
    Aliment Pharmacol Ther. 2021;53:660.
    PubMed    


  216. LAHARIE D
    Editorial: is enteral nutrition back in acute severe ulcerative colitis?
    Aliment Pharmacol Ther. 2021;53:745-746.
    PubMed    


  217. AL-ANI AH, Prentice RE, Rentsch C, Christensen B, et al
    Letter: SARS-CoV-2 infection in two inflammatory bowel disease patients treated with dual targeted therapy-Authors' reply.
    Aliment Pharmacol Ther. 2021;53:766-767.
    PubMed    


  218. SAHU P, Kedia S, Kumar Vuyyuru S, Travis S, et al
    Editorial: is enteral nutrition back in acute severe ulcerative colitis? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:747-748.
    PubMed    


  219. O'MORAIN N, Coe C, Mallon P, Twomey P, et al
    Letter: how frequently does COVID-19 mimic an IBD flare when community transmission of SARS-CoV-2 is active?
    Aliment Pharmacol Ther. 2021;53:674-675.
    PubMed    


  220. PRIVITERA G, Pugliese D, Scaldaferri F, Armuzzi A, et al
    Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapy.
    Aliment Pharmacol Ther. 2021;53:764-765.
    PubMed    


  221. TRYSTRAM N, Abitbol V, Tannoury J, Lecomte M, et al
    Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study.
    Aliment Pharmacol Ther. 2021 Mar 1. doi: 10.1111/apt.16312.
    PubMed     Abstract available


  222. KANESHIRO M, Takenaka K, Suzuki K, Fujii T, et al
    Pancolonic endoscopic and histologic evaluation for relapse prediction in patients with ulcerative colitis in clinical remission.
    Aliment Pharmacol Ther. 2021 Mar 1. doi: 10.1111/apt.16310.
    PubMed     Abstract available


  223. MANTZARIS GJ, Bamias G
    Editorial: an expert consensus to standardise the assessment of histologic disease activity in Crohn's disease clinical trials-a missing link.
    Aliment Pharmacol Ther. 2021;53:749-750.
    PubMed    


  224. ROBLIN X, Paul S, Nancey S
    Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game.
    Aliment Pharmacol Ther. 2021;53:640-641.
    PubMed    


  225. RUNDQUIST S, Sachs MC, Eriksson C, Olen O, et al
    Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game-authors' reply.
    Aliment Pharmacol Ther. 2021;53:642-643.
    PubMed    


  226. MCCURDY J, Boet S, Rosenfeld G
    Editorial: is hyperbaric oxygen a therapeutic opportunity for refractory perianal Crohn's disease?
    Aliment Pharmacol Ther. 2021;53:667-668.
    PubMed    


  227. LAFEUILLE P, Hordonneau C, Vignette J, Blayac L, et al
    Transmural healing and MRI healing are associated with lower risk of bowel damage progression than endoscopic mucosal healing in Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:577-586.
    PubMed     Abstract available


  228. LANSDORP CA, Gecse KB, Buskens CJ, Lowenberg M, et al
    Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:587-597.
    PubMed     Abstract available


    February 2021
  229. FLANAGAN E, Wright EK, Hardikar W, Sparrow MP, et al
    Maternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonates.
    Aliment Pharmacol Ther. 2021 Feb 19. doi: 10.1111/apt.16294.
    PubMed     Abstract available


  230. JAHRAUS CD
    Editorial: "Please Sir, I want some more" data to guide delivery of abdominopelvic radiotherapy in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021;53:454-455.
    PubMed    


  231. AXELRAD JE
    Editorial: immune-mediated diseases-are we closer to disease-defining molecular signatures?
    Aliment Pharmacol Ther. 2021;53:563-564.
    PubMed    


  232. DANESE S, Subramaniam K, Van Zyl J, Adsul S, et al
    Editorial: vedolizumab in inflammatory bowel diseases-less is more? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:445-446.
    PubMed    


  233. WILS P, Pariente B
    Editorial: keep calm and carry on-managing non-TNF antagonist biologics in pregnancy-authors' reply.
    Aliment Pharmacol Ther. 2021;53:452-453.
    PubMed    


  234. SEOW CH, Ma C
    Keep calm and carry on-managing non-TNF antagonist biologics in pregnancy.
    Aliment Pharmacol Ther. 2021;53:450-451.
    PubMed    


  235. TOWNSEND T, Subramanian S
    Editorial: vedolizumab in inflammatory bowel diseases-less is more?
    Aliment Pharmacol Ther. 2021;53:443-444.
    PubMed    


  236. MESERVE J, Facciorusso A, Holmer AK, Annese V, et al
    Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2021;53:374-382.
    PubMed     Abstract available


    January 2021
  237. RHUDY C, Perry CL, Singleton M, Talbert J, et al
    Chronic opioid use is associated with early biologic discontinuation in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Jan 26. doi: 10.1111/apt.16269.
    PubMed     Abstract available


  238. SAHU P, Kedia S, Vuyyuru SK, Bajaj A, et al
    Randomised clinical trial: exclusive enteral nutrition versus standard of care for acute severe ulcerative colitis.
    Aliment Pharmacol Ther. 2021 Jan 13. doi: 10.1111/apt.16249.
    PubMed     Abstract available


  239. CHEE D, Kennedy NA, Goodhand JR, Ahmad T, et al
    Editorial: missed opportunities to detect colorectal cancer in inflammatory bowel disease-getting to the root. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:337-338.
    PubMed    


  240. MAHMOUD R, Itzkowitz SH
    Editorial: missed opportunities to detect colorectal cancer in inflammatory bowel disease-getting to the root.
    Aliment Pharmacol Ther. 2021;53:335-336.
    PubMed    


  241. LORD A, Radford-Smith G
    Letter: hidden costs in healthcare use for incident and prevalent Crohn's disease and ulcerative colitis.
    Aliment Pharmacol Ther. 2021;53:368-369.
    PubMed    


  242. RIMOLA J, Panes J, Ordas I
    Letter: accuracy of magnetic resonance index of activity score to predict response to biologics in Crohn's disease-authors' reply.
    Aliment Pharmacol Ther. 2021;53:207-208.
    PubMed    


  243. DEBNATH P, Rathi P
    Letter: accuracy of magnetic resonance index of activity score to predict response to biologics in Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:205-206.
    PubMed    


  244. MURRAY CD
    Editorial: fatigue-difficult to assess and difficult to treat.
    Aliment Pharmacol Ther. 2021;53:339.
    PubMed    


  245. LEBLANC JF, Hart AL
    Editorial: a pipe dream fulfilled? A therapeutic option for fatigue in IBD.
    Aliment Pharmacol Ther. 2021;53:342-343.
    PubMed    


  246. TOWNSEND T, Subramanian S
    Letter: propensity score-handle with care. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:362-363.
    PubMed    


  247. MACALUSO FS, Orlando A
    Letter: propensity score-handle with care.
    Aliment Pharmacol Ther. 2021;53:360-361.
    PubMed    


  248. CARBERY I, Selinger CP
    Editorial: can serum triiodothyronine-to-thyroxine (T3/T4) ratio predict safety and efficacy of biologic treatment in IBD?
    Aliment Pharmacol Ther. 2021;53:346-347.
    PubMed    


  249. BAGER P, Hvas CL, Rud CL, Dahlerup JF, et al
    Editorial: a pipe dream fulfilled? A therapeutic option for fatigue in IBD. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:344-345.
    PubMed    


  250. SCHREINER P, von Kanel R, Misselwitz B
    Editorial: fatigue-difficult to assess and difficult to treat. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:340-341.
    PubMed    


  251. BERTANI L, Pugliese D, Trico D, Costa F, et al
    Editorial: can serum triiodothyronine-to-thyroxine (T3/T4) ratio predict safety and efficacy of biologic treatment in IBD? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:348-349.
    PubMed    


  252. NICE R, Chanchlani N, Green H, Bewshea C, et al
    Validating the positivity thresholds of drug-tolerant anti-infliximab and anti-adalimumab antibody assays.
    Aliment Pharmacol Ther. 2021;53:128-137.
    PubMed     Abstract available


  253. DANESE S, Subramaniam K, Van Zyl J, Adsul S, et al
    Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme.
    Aliment Pharmacol Ther. 2021;53:265-272.
    PubMed     Abstract available


  254. BERTANI L, Trico D, Pugliese D, Privitera G, et al
    Serum triiodothyronine-to-thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients.
    Aliment Pharmacol Ther. 2021;53:273-280.
    PubMed     Abstract available


  255. FRAZZONI L, La Marca M, Radaelli F, Spada C, et al
    Systematic review with meta-analysis: the appropriateness of colonoscopy increases the probability of relevant findings and cancer while reducing unnecessary exams.
    Aliment Pharmacol Ther. 2021;53:22-32.
    PubMed     Abstract available


  256. PAI RK, Pai RK, Brown I, Choi WT, et al
    The significance of histological activity measurements in immune checkpoint inhibitor colitis.
    Aliment Pharmacol Ther. 2021;53:150-159.
    PubMed     Abstract available


  257. UNGARO RC, Hu L, Ji J, Nayar S, et al
    Machine learning identifies novel blood protein predictors of penetrating and stricturing complications in newly diagnosed paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:281-290.
    PubMed     Abstract available


  258. KING D, Coupland B, Dosanjh A, Cole A, et al
    The risk of later surgery at the anastomotic site following right hemicolectomy for Crohn's disease in a national cohort of 12 230 patients.
    Aliment Pharmacol Ther. 2021;53:114-127.
    PubMed     Abstract available


    December 2020
  259. RUNDQUIST S, Sachs MC, Eriksson C, Olen O, et al
    Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers.
    Aliment Pharmacol Ther. 2020 Dec 19. doi: 10.1111/apt.16193.
    PubMed     Abstract available


  260. YE L, Chapman TP, Wen Z, Lin L, et al
    Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti-TNF therapy in a tuberculosis endemic region.
    Aliment Pharmacol Ther. 2020 Dec 12. doi: 10.1111/apt.16130.
    PubMed     Abstract available


  261. PIOVANI D, Pansieri C, Peyrin-Biroulet L, Danese S, et al
    Confounding and bias in observational studies in inflammatory bowel disease: a meta-epidemiological study.
    Aliment Pharmacol Ther. 2020 Dec 9. doi: 10.1111/apt.16222.
    PubMed     Abstract available


  262. WILS P, Seksik P, Stefanescu C, Nancey S, et al
    Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study.
    Aliment Pharmacol Ther. 2020 Dec 7. doi: 10.1111/apt.16192.
    PubMed     Abstract available


  263. LO CH, Khalili H, Lochhead P, Song M, et al
    Immune-mediated diseases and risk of Crohn's disease or ulcerative colitis: a prospective cohort study.
    Aliment Pharmacol Ther. 2020 Dec 5. doi: 10.1111/apt.16210.
    PubMed     Abstract available


  264. WORLEY G, Almoudaris A, Bassett P, Segal J, et al
    Colectomy rates for ulcerative colitis in England 2003-2016.
    Aliment Pharmacol Ther. 2020 Dec 2. doi: 10.1111/apt.16202.
    PubMed     Abstract available


  265. REUKEN PA, Wust M, Loffler B, Bauer M, et al
    Letter: SARS-CoV-2-induced gastrointestinal inflammation.
    Aliment Pharmacol Ther. 2020;52.
    PubMed    


    November 2020
  266. DOHOS D, Hanak L, Szakacs Z, Kiss S, et al
    Systematic review with meta-analysis: the effects of immunomodulator or biological withdrawal from mono- or combination therapy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Nov 28. doi: 10.1111/apt.16182.
    PubMed     Abstract available


  267. BROUSSARD D, Riviere P, Bonnet J, Fotsing G, et al
    Impact of abdominal or pelvic radiotherapy on disease activity in inflammatory bowel disease: a multicentre cohort study from the GETAID.
    Aliment Pharmacol Ther. 2020 Nov 26. doi: 10.1111/apt.16176.
    PubMed     Abstract available


  268. BAGER P, Hvas CL, Rud CL, Dahlerup JF, et al
    Randomised clinical trial: high-dose oral thiamine versus placebo for chronic fatigue in patients with quiescent inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Nov 18. doi: 10.1111/apt.16166.
    PubMed     Abstract available


  269. HIBIYA S, Matsuyama Y, Fujii T, Maeyashiki C, et al
    5-aminosalicylate-intolerant patients are at increased risk of colectomy for ulcerative colitis.
    Aliment Pharmacol Ther. 2020 Nov 7. doi: 10.1111/apt.16120.
    PubMed     Abstract available


  270. SCHREINER P, Rossel JB, Biedermann L, Valko PO, et al
    Fatigue in inflammatory bowel disease and its impact on daily activities.
    Aliment Pharmacol Ther. 2020 Nov 7. doi: 10.1111/apt.16145.
    PubMed     Abstract available


  271. GORDON C, Chee D, Hamilton B, Heerasing NM, et al
    Root-cause analyses of missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Nov 7. doi: 10.1111/apt.16155.
    PubMed     Abstract available


  272. MEYER A, Drouin J, Weill A, Carbonnel F, et al
    Pregnancy in women with inflammatory bowel disease: a French nationwide study 2010-2018.
    Aliment Pharmacol Ther. 2020;52:1480-1490.
    PubMed     Abstract available


  273. NICOLAIDES S, Vasudevan A, van Langenberg D
    Letter: rationalising aminosalicylates in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020;52:1619-1620.
    PubMed    


  274. MA C, Singh S, Heatherington J, Panaccione R, et al
    Editorial: is age just a number when it comes to treatment of inflammatory bowel disease?
    Aliment Pharmacol Ther. 2020;52:1615-1616.
    PubMed    


  275. ASSCHER VER, Biemans VBC, Hoentjen F, Maljaars PWJ, et al
    Editorial: is age just a number when it comes to treatment of inflammatory bowel disease? Authors' reply.
    Aliment Pharmacol Ther. 2020;52:1617-1618.
    PubMed    


  276. CHAPMAN TP, Frias Gomes C, Louis E, Colombel JF, et al
    Letter: rationalising aminosalicylates in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2020;52:1621.
    PubMed    


  277. NARULA N, Aruljothy A, Alshahrani AA, Fadida M, et al
    Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission.
    Aliment Pharmacol Ther. 2020 Nov 1. doi: 10.1111/apt.16147.
    PubMed     Abstract available


  278. VASUDEVAN A, Con D, Nicolaides S, van Langenberg DR, et al
    Editorial: methotrexate vs azathioprine-do differential rates of discontinuation settle the debate? Authors' reply.
    Aliment Pharmacol Ther. 2020;52:1529-1530.
    PubMed    


  279. ZULFIQAR M, Deepak P
    Editorial: crystal gazing with magnetic resonance enterography to predict the response to TNF-alpha inhibitors in Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:1531-1532.
    PubMed    


  280. FRASER AG
    Methotrexate or azathioprine-do differing rates of discontinuation settle the debate?
    Aliment Pharmacol Ther. 2020;52:1527-1528.
    PubMed    


  281. FLANAGAN E, Gibson PR, Wright EK, Moore GT, et al
    Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure.
    Aliment Pharmacol Ther. 2020;52:1551-1562.
    PubMed     Abstract available


  282. TAYLOR H, Serrano-Contreras JI, McDonald JAK, Epstein J, et al
    Multiomic features associated with mucosal healing and inflammation in paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:1491-1502.
    PubMed     Abstract available


  283. RIMOLA J, Fernandez-Clotet A, Capozzi N, Rojas-Farreras S, et al
    Pre-treatment magnetic resonance enterography findings predict the response to TNF-alpha inhibitors in Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:1563-1573.
    PubMed     Abstract available


    October 2020
  284. BANERJEE R, Ravikanth VV, Pal P, Bale G, et al
    NUDT15 C415T variant compared with TPMT genotyping in predicting azathioprine-induced leucopenia: prospective analysis of 1014 inflammatory bowel disease patients in India.
    Aliment Pharmacol Ther. 2020 Oct 27. doi: 10.1111/apt.16137.
    PubMed     Abstract available


  285. PANACCIONE R, Danese S, Sandborn WJ, O'Brien CD, et al
    Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.
    Aliment Pharmacol Ther. 2020 Oct 21. doi: 10.1111/apt.16119.
    PubMed     Abstract available


  286. AMIOT A, Salameh R
    Letter: long-term outcomes of patients with acute severe ulcerative colitis after intravenous steroid therapy-authors' reply.
    Aliment Pharmacol Ther. 2020;52:1252.
    PubMed    


  287. FABIAN A, Bor R, Farkas K, Szepes Z, et al
    Letter: long-term outcomes of patients with acute severe ulcerative colitis after intravenous steroid therapy.
    Aliment Pharmacol Ther. 2020;52:1251.
    PubMed    


  288. PRENTICE RE, Tjandra D, Garg M, Lubel JS, et al
    Letter: ACE2, IBD and COVID-19-why IBD patients may be at reduced risk of COVID-19.
    Aliment Pharmacol Ther. 2020;52:1422-1423.
    PubMed    


  289. BRITTON E, Richardson P, Mian I, Conley T, et al
    Letter: Covid-19-re-initiating clinical services for chronic gastrointestinal diseases. How and when?
    Aliment Pharmacol Ther. 2020;52:1414-1415.
    PubMed    


  290. BIEMANS VBC, Hoentjen F, Pierik MJ
    Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:1255-1256.
    PubMed    


  291. LIU K, Cai F, Huang J
    Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth?
    Aliment Pharmacol Ther. 2020;52:1253-1254.
    PubMed    


  292. LAHARIE D, Riviere P
    Editorial: biologics in the therapy of Crohn's disease-the fog clears.
    Aliment Pharmacol Ther. 2020;52:1214-1215.
    PubMed    


  293. MERTZ NORGARD B, Friedman S
    Editorial: thiopurine/anti-TNF use during pregnancy-more encouraging safety data. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:1411.
    PubMed    


  294. BETTENWORTH D, Bokemeyer A, Kou L, Lopez R, et al
    Systematic review with meta-analysis: efficacy of balloon-assisted enteroscopy for dilation of small bowel Crohn's disease strictures.
    Aliment Pharmacol Ther. 2020;52:1104-1116.
    PubMed     Abstract available


  295. TOWNSEND T, Razanskaite V, Dodd S, Storey D, et al
    Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:1341-1352.
    PubMed     Abstract available


    September 2020
  296. BATTAT R, Vande Casteele N, Pai RK, Wang Z, et al
    Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study.
    Aliment Pharmacol Ther. 2020 Sep 27. doi: 10.1111/apt.16083.
    PubMed     Abstract available


  297. CAENEPEEL C, Sadat Seyed Tabib N, Vieira-Silva S, Vermeire S, et al
    Review article: how the intestinal microbiota may reflect disease activity and influence therapeutic outcome in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Sep 24. doi: 10.1111/apt.16096.
    PubMed     Abstract available


  298. ASSCHER VER, Biemans VBC, Pierik MJ, Dijkstra G, et al
    Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease-a prospective multicentre cohort study.
    Aliment Pharmacol Ther. 2020 Sep 9. doi: 10.1111/apt.16073.
    PubMed     Abstract available


  299. LOFTUS EV JR, Feagan BG, Panaccione R, Colombel JF, et al
    Long-term safety of vedolizumab for inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Sep 2. doi: 10.1111/apt.16060.
    PubMed     Abstract available


  300. VASUDEVAN A, van Langenberg DR
    Editorial: direct costs are only the tip of the iceberg in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020;52:879-880.
    PubMed    


  301. LOVATT J, Selinger CP
    Letter: recognising frailty in patients with inflammatory bowel disease is crucial for appropriate personalised treatment.
    Aliment Pharmacol Ther. 2020;52:908-909.
    PubMed    


  302. QURAISHI MN, Segal JP, Cooney R, Kennedy NA, et al
    Letter: online search trends suggest patient concerns around immunosuppression use in inflammatory bowel disease during COVID-19 in the United Kingdom.
    Aliment Pharmacol Ther. 2020;52:937-939.
    PubMed    


  303. JANGI S, Yoon H, Dulai PS, Valasek M, et al
    Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing.
    Aliment Pharmacol Ther. 2020;52:1008-1016.
    PubMed     Abstract available


  304. CHEE D, Goodhand JR, Ahmad T
    Editorial: is pharmacogenetic testing for adverse effects to IBD treatments ready for roll-out?
    Aliment Pharmacol Ther. 2020;52:1076-1077.
    PubMed    


  305. APPLETON L, Day AS
    Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab.
    Aliment Pharmacol Ther. 2020;52:1080-1081.
    PubMed    


  306. ROBLIN X, Le Roy B, Paul S
    Editorial: therapeutic drug monitoring for golimumab - ready for prime time?
    Aliment Pharmacol Ther. 2020;52:1078-1079.
    PubMed    


  307. BERTANI L, Fornai M, Antonioli L, Blandizzi C, et al
    Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab-authors' reply.
    Aliment Pharmacol Ther. 2020;52:1082.
    PubMed    


  308. KOPYLOV U
    Letter: optimising response to ustekinumab therapy for patients with Crohn's disease-author's reply.
    Aliment Pharmacol Ther. 2020;52:907.
    PubMed    


  309. DESAI D, Abraham P
    Letter: monitoring interval for thiopurine therapy - a comment.
    Aliment Pharmacol Ther. 2020;52:910.
    PubMed    


  310. HUDSON J, Herfarth HH, Barnes EL
    Letter: optimising response to ustekinumab therapy for patients with Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:906.
    PubMed    


  311. JONES K, Baker K, Speight RA, Thompson NP, et al
    Randomised clinical trial: combined impact and resistance training in adults with stable Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:964-975.
    PubMed     Abstract available


  312. BROMS G, Kieler H, Ekbom A, Gissler M, et al
    Paediatric infections in the first 3 years of life after maternal anti-TNF treatment during pregnancy.
    Aliment Pharmacol Ther. 2020;52:843-854.
    PubMed     Abstract available


  313. IBORRA M, Beltran B, Fernandez-Clotet A, Iglesias-Flores E, et al
    Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry.
    Aliment Pharmacol Ther. 2020;52:1017-1030.
    PubMed     Abstract available


    August 2020
  314. CHUPIN A, Perduca V, Meyer A, Bellanger C, et al
    Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Aug 25. doi: 10.1111/apt.16050.
    PubMed     Abstract available


  315. VASUDEVAN A, Parthasarathy N, Con D, Nicolaides S, et al
    Thiopurines vs methotrexate: Comparing tolerability and discontinuation rates in the treatment of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Aug 14. doi: 10.1111/apt.16039.
    PubMed     Abstract available


  316. DULAI PS, Raffals LE, Hudesman D, Chiorean M, et al
    A phase 2B randomised trial of hyperbaric oxygen therapy for ulcerative colitis patients hospitalised for moderate to severe flares.
    Aliment Pharmacol Ther. 2020 Aug 3. doi: 10.1111/apt.15984.
    PubMed     Abstract available


  317. RESAL T, Pigniczki D, Szanto K, Rutka M, et al
    Letter: ciclosporin and vedolizumab for steroid-refractory ulcerative colitis.
    Aliment Pharmacol Ther. 2020;52:578-579.
    PubMed    


  318. GARG M, Royce SG, Lubel JS
    Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2-exploring RAS inhibitors.
    Aliment Pharmacol Ther. 2020;52:569-570.
    PubMed    


  319. YANG E, Panaccione N, Whitmire N, Dulai PS, et al
    Letter: combination of biologics in inflammatory bowel diseases. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:568-569.
    PubMed    


  320. KOPYLOV U
    Letter: ustekinumab dose intensification for loss of response-should we re-induce before shortening the dose interval? Author's reply.
    Aliment Pharmacol Ther. 2020;52:565-566.
    PubMed    


  321. HRON BM, Cohen RD, Johnson SJ, Skup M, et al
    Letter: is unrealised adult height resulting from paediatric Crohn's disease associated with a potential reduction in lifetime earnings?
    Aliment Pharmacol Ther. 2020;52:559-560.
    PubMed    


  322. SRINIVASAN A, De Cruz P, van Langenberg DR
    Letter: ustekinumab dose intensification for loss of response-should we re-induce before shortening the dose interval?
    Aliment Pharmacol Ther. 2020;52:564-565.
    PubMed    


  323. MOURATIDOU N, Malmborg P, Olen O
    Letter: is unrealised adult height resulting from paediatric Crohn's disease associated with a potential reduction in lifetime earnings? Authors' reply.
    Aliment Pharmacol Ther. 2020;52:560-561.
    PubMed    


  324. ALRIC H, Amiot A, Carbonnel F, Meyer A, et al
    Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:563-564.
    PubMed    


  325. K HOLMER A, Singh S
    Editorial: pancreatic cancer risk in inflammatory bowel diseases-it's all relative.
    Aliment Pharmacol Ther. 2020;52:550-551.
    PubMed    


  326. SRINIVASAN A, De Cruz P, van Langenberg DR
    Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail.
    Aliment Pharmacol Ther. 2020;52:561-562.
    PubMed    


  327. FUMERY M, Yzet C, Brazier F
    Letter: combination of biologics in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2020;52:566-567.
    PubMed    


  328. KHALILI H, Everhov AH, Halfvarson J, Ludvigsson JF, et al
    Healthcare use, work loss and total costs in incident and prevalent Crohn's disease and ulcerative colitis: results from a nationwide study in Sweden.
    Aliment Pharmacol Ther. 2020;52:655-668.
    PubMed     Abstract available


  329. TAXONERA C, Alba C
    Editorial: social distancing during the COVID-19 pandemic-IBD patients cannot stay at home forever. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:719-720.
    PubMed    


  330. BENSON-POPE SJ, Gearry RB
    Editorial: social distancing during the COVID-19 pandemic - IBD patients cannot stay at home forever.
    Aliment Pharmacol Ther. 2020;52:717-718.
    PubMed    


  331. KHAN MU, Mushtaq K, Al-Ejji KMAA, Yakoob RA, et al
    Letter: IBD nurse-a pivotal role in the time of the pandemic.
    Aliment Pharmacol Ther. 2020;52:745.
    PubMed    


  332. BERTANI L, Antonioli L, Blandizzi C
    Letter: ustekinumab's effectiveness outcomes compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers?
    Aliment Pharmacol Ther. 2020;52:751-752.
    PubMed    


  333. AL-ANI AH, Rentsch CA, Azim S, Bidgood E, et al
    Letter: IBD nurse-pivotal role in the time of the pandemic. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:746-747.
    PubMed    


  334. BIEMANS VBC, Hoentjen F, Pierik MJ
    Letter: ustekinumab's effectiveness compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers? Authors' reply.
    Aliment Pharmacol Ther. 2020;52:753-754.
    PubMed    


  335. MARSH A, Radford-Smith G
    Editorial: obesity management and IBD-weight loss reduces IBD risk.
    Aliment Pharmacol Ther. 2020;52:731-732.
    PubMed    


  336. KANG B, Kim TJ, Choi J, Baek SY, et al
    Adjustment of azathioprine dose should be based on a lower 6-TGN target level to avoid leucopenia in NUDT15 intermediate metabolisers.
    Aliment Pharmacol Ther. 2020;52:459-470.
    PubMed     Abstract available


  337. WALKER GJ, Lin S, Chanchlani N, Thomas A, et al
    Quality improvement project identifies factors associated with delay in IBD diagnosis.
    Aliment Pharmacol Ther. 2020;52:471-480.
    PubMed     Abstract available


  338. BOHM M, Xu R, Zhang Y, Varma S, et al
    Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:669-681.
    PubMed     Abstract available


  339. SEGAL JP, Smith PJ
    Editorial: quality improvement project to identify factors associated with a delay in IBD diagnosis.
    Aliment Pharmacol Ther. 2020;52:733-734.
    PubMed    


    July 2020
  340. LANSDORP CA, Buskens CJ, Gecse KB, D'Haens GRAM, et al
    Letter: off-label use of hyperbaric oxygen therapy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020;52:215-216.
    PubMed    


  341. SIMSEK M, de Boer NKH
    Letter: off-label use of hyperbaric oxygen therapy in inflammatory bowel disease-Authors' reply.
    Aliment Pharmacol Ther. 2020;52:216-217.
    PubMed    


  342. DETLIE TE, Jahnsen J
    Editorial: improving precision of iron deficiency diagnosis in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020;52:400.
    PubMed    


  343. DEEPAK P, Itani M
    Editorial: transperineal ultrasound in addition to a transabdominal ultrasound in ulcerative colitis-one more arrow in the quiver of non-invasive diagnostics.
    Aliment Pharmacol Ther. 2020;52:401-402.
    PubMed    


  344. SAGAMI S, Kobayashi T, Hibi T
    Editorial: transperineal ultrasound in addition to a transabdominal ultrasound in ulcerative colitis-one more arrow in the quiver of non-invasive diagnostics. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:403.
    PubMed    


  345. DAUDE S, Gastin I, Peyrin-Biroulet L
    Editorial: diagnostic precision of iron deficiency in inflammatory bowel disease. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:401.
    PubMed    


  346. TAXONERA C, Sagastagoitia I, Alba C, Manas N, et al
    2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2020;52:276-283.
    PubMed     Abstract available


  347. ABDEL-DAIM MM
    Editorial: the road to elimination of viral hepatitis-another promising real-world experience.
    Aliment Pharmacol Ther. 2020;52:405-406.
    PubMed    


  348. GARG M, Chand S, Weenink P, Yunqiu Wu K, et al
    Letter: assessing iron deficiency in patients with IBD-a step in the right direction, but uncertainty remains.
    Aliment Pharmacol Ther. 2020;52:413-415.
    PubMed    


  349. TOWNSEND T, Probert C
    Editorial: peristomal pyoderma gangrenosum-a challenge for patients, healthcare professionals and research.
    Aliment Pharmacol Ther. 2020;52:404-405.
    PubMed    


  350. BIEMANS VBC, van der Woude CJ, Dijkstra G, van der Meulen-de Jong AE, et al
    Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment.
    Aliment Pharmacol Ther. 2020;52:123-134.
    PubMed     Abstract available


  351. KABIR M, Fofaria R, Arebi N, Bassett P, et al
    Systematic review with meta-analysis: IBD-associated colonic dysplasia prognosis in the videoendoscopic era (1990 to present).
    Aliment Pharmacol Ther. 2020;52:5-19.
    PubMed     Abstract available


  352. KOPYLOV U, Hanzel J, Liefferinckx C, De Marco D, et al
    Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy.
    Aliment Pharmacol Ther. 2020;52:135-142.
    PubMed     Abstract available


  353. KOCHAR B, Cai W, Cagan A, Ananthakrishnan AN, et al
    Frailty is independently associated with mortality in 11 001 patients with inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2020;52:311-318.
    PubMed     Abstract available


  354. THOMANN AK, Mak JWY, Zhang JW, Wuestenberg T, et al
    Review article: bugs, inflammation and mood-a microbiota-based approach to psychiatric symptoms in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2020;52:247-266.
    PubMed     Abstract available


  355. DUMONT LM, Landman C, Sokol H, Beaugerie L, et al
    Increased risk of permanent stoma in Crohn's disease associated with hidradenitis suppurativa: a case-control study.
    Aliment Pharmacol Ther. 2020;52:303-310.
    PubMed     Abstract available


  356. BERTANI L, Fornai M, Fornili M, Antonioli L, et al
    Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab.
    Aliment Pharmacol Ther. 2020;52:284-291.
    PubMed     Abstract available


    June 2020
  357. SINGH S, Kim J, Zhu W, Dulai PS, et al
    No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy.
    Aliment Pharmacol Ther. 2020 Jun 23. doi: 10.1111/apt.15876.
    PubMed     Abstract available


  358. SAMAAN MA, Cunningham G, Tamilarasan AG, Beltran L, et al
    Therapeutic thresholds for golimumab serum concentrations during induction and maintenance therapy in ulcerative colitis: results from the GO-LEVEL study.
    Aliment Pharmacol Ther. 2020 Jun 7. doi: 10.1111/apt.15808.
    PubMed     Abstract available


  359. ALBSHESH A, Ben-Horin S
    Editorial: which biologic is next for ulcerative colitis patients who fail a subcutaneous anti-TNF?
    Aliment Pharmacol Ther. 2020;51:1198-1199.
    PubMed    


  360. SANDBORN WJ, Panes J, Sands BE, Reinisch W, et al
    Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice. Authors' reply.
    Aliment Pharmacol Ther. 2020;51:1209-1210.
    PubMed    


  361. SANTA A, Szanto KJ, Sarlos P, Miheller P, et al
    Letter: suicide risk among adult inflammatory bowel disease patients.
    Aliment Pharmacol Ther. 2020;51:1213-1214.
    PubMed    


  362. KOTZE PG, Teixeira FV, Damiao AOMC
    Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice.
    Aliment Pharmacol Ther. 2020;51:1208-1209.
    PubMed    


  363. MALHAM M, Jakobsen C, Paerregaard A, Hald M, et al
    Letter: suicide risk among adult inflammatory bowel disease patients. Authors' reply.
    Aliment Pharmacol Ther. 2020;51:1214-1215.
    PubMed    


  364. LI WAI SUEN CFD, Choy MC, De Cruz P
    Letter: how can we reduce mortality in elderly patients with acute severe ulcerative colitis?
    Aliment Pharmacol Ther. 2020;51:1444-1445.
    PubMed    


  365. DONG C, Metzger M, Holsbo EE, Perduca V, et al
    Letter: how can we reduce mortality in elderly patients with acute severe ulcerative colitis? Authors' reply.
    Aliment Pharmacol Ther. 2020;51:1445-1446.
    PubMed    


  366. BENSON-POPE SJ, Gearry RB
    Editorial: increasing IBD prevalence and its complications in the context of the COVID-19 pandemic.
    Aliment Pharmacol Ther. 2020;51:1441-1442.
    PubMed    


  367. KING DS, Trudgill NJ, Adderley NJ
    Editorial: increasing IBD prevalence and its complications in the context of the COVID-19 pandemic. Authors' reply.
    Aliment Pharmacol Ther. 2020;51:1442-1443.
    PubMed    


  368. RHODES JM, Subramanian S, Laird E, Kenny RA, et al
    Editorial: low population mortality from COVID-19 in countries south of latitude 35 degrees North supports vitamin D as a factor determining severity.
    Aliment Pharmacol Ther. 2020;51:1434-1437.
    PubMed    


  369. CREEMERS RH, Bloem S, van Bodegraven AA
    Editorial: the most commonly used IBD indices still fail to represent real life and subjective patient experience.
    Aliment Pharmacol Ther. 2020;51:1202-1203.
    PubMed    


  370. PARIENTE B
    Editorial: the most commonly used IBD indices still fail to represent real life and subjective patient experience. Author's reply.
    Aliment Pharmacol Ther. 2020;51:1203-1204.
    PubMed    


  371. SCRIVO B, Renna S, Casa A, Monachino N, et al
    Letter: mesalazine-a safe drug with rare serious adverse events.
    Aliment Pharmacol Ther. 2020;51:1210-1211.
    PubMed    


  372. SEHGAL P, Narula N
    Letter: mesalazine-a safe drug with rare serious adverse events? Authors' reply.
    Aliment Pharmacol Ther. 2020;51:1212.
    PubMed    


  373. MICELI MC, Arcuri C, Renna S, Orlando A, et al
    Letter: golimumab efficacy in patients with Crohn's disease and concomitant severe arthritis.
    Aliment Pharmacol Ther. 2020;51:1449-1451.
    PubMed    


  374. YANG E, Panaccione N, Whitmire N, Dulai PS, et al
    Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.
    Aliment Pharmacol Ther. 2020;51:1031-1038.
    PubMed     Abstract available


  375. LU C, Baraty B, Lee Robertson H, Filyk A, et al
    Systematic review: medical therapy for fibrostenosing Crohn's disease.
    Aliment Pharmacol Ther. 2020;51:1233-1246.
    PubMed     Abstract available


  376. SRINIVASAN A, van Langenberg DR, Little RD, Sparrow MP, et al
    A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn's disease.
    Aliment Pharmacol Ther. 2020;51:1342-1352.
    PubMed     Abstract available


  377. PAPOUTSOPOULOU S, Satsangi J, Campbell BJ, Probert CS, et al
    Review article: impact of cigarette smoking on intestinal inflammation-direct and indirect mechanisms.
    Aliment Pharmacol Ther. 2020;51:1268-1285.
    PubMed     Abstract available


  378. CZAJA AJ
    Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis.
    Aliment Pharmacol Ther. 2020;51:1286-1304.
    PubMed     Abstract available


    May 2020
  379. CHAPMAN TP, Frias Gomes C, Louis E, Colombel JF, et al
    Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 May 26. doi: 10.1111/apt.15771.
    PubMed     Abstract available


  380. SHAH A, Talley NJ, Koloski N, Macdonald GA, et al
    Duodenal bacterial load as determined by quantitative polymerase chain reaction in asymptomatic controls, functional gastrointestinal disorders and inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 May 15. doi: 10.1111/apt.15786.
    PubMed     Abstract available


  381. EVERHOV AH, Erichsen R, Sachs MC, Pedersen L, et al
    Inflammatory bowel disease and pancreatic cancer: a Scandinavian register-based cohort study 1969-2017.
    Aliment Pharmacol Ther. 2020 May 15. doi: 10.1111/apt.15785.
    PubMed     Abstract available


  382. WANG J, Prenner J, Wang W, Sakuraba A, et al
    Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 May 7. doi: 10.1111/apt.15766.
    PubMed     Abstract available


  383. SAGAMI S, Kobayashi T, Aihara K, Umeda M, et al
    Transperineal ultrasound predicts endoscopic and histological healing in ulcerative colitis.
    Aliment Pharmacol Ther. 2020 May 7. doi: 10.1111/apt.15767.
    PubMed     Abstract available


  384. AXELRAD JE, Cadwell KH, Colombel JF, Shah SC, et al
    Systematic review: gastrointestinal infection and incident inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 May 5. doi: 10.1111/apt.15770.
    PubMed     Abstract available


  385. BANGMA A, Voskuil MD, Uniken Venema WTC, Brugge H, et al
    Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 May 3. doi: 10.1111/apt.15762.
    PubMed     Abstract available


  386. SANDS BE, Armuzzi A, Marshall JK, Lindsay JO, et al
    Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply.
    Aliment Pharmacol Ther. 2020;51:997-998.
    PubMed    


  387. PENG C, Jiexin L, Yue W, Benhong Z, et al
    Letter: corticosteroid use alongside tofacitinib in OCTAVE Open.
    Aliment Pharmacol Ther. 2020;51:996-997.
    PubMed    


  388. LAUBE R, Selinger CP
    Letter: pregnant women with IBD are more likely to be adherent to biologic therapies than other medications.
    Aliment Pharmacol Ther. 2020;51:915-916.
    PubMed    


  389. LEE S, Seow CH, Adhikari K, Metcalfe A, et al
    Letter: pregnant women with IBD are more likely to be adherent to biologic therapies than other medications-authors' reply.
    Aliment Pharmacol Ther. 2020;51:916-917.
    PubMed    


  390. UNGAR B, Kopylov U
    Editorial: is vedolizumab effective for perianal Crohn's disease?
    Aliment Pharmacol Ther. 2020;51:912-913.
    PubMed    


  391. LOGAN M, Gkikas K, Svolos V, Nichols B, et al
    Analysis of 61 exclusive enteral nutrition formulas used in the management of active Crohn's disease-new insights into dietary disease triggers.
    Aliment Pharmacol Ther. 2020;51:935-947.
    PubMed     Abstract available


  392. ALRIC H, Amiot A, Kirchgesner J, Treton X, et al
    The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor.
    Aliment Pharmacol Ther. 2020;51:948-957.
    PubMed     Abstract available


  393. UNGARO RC, Aggarwal S, Topaloglu O, Lee WJ, et al
    Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease.
    Aliment Pharmacol Ther. 2020;51:831-842.
    PubMed     Abstract available


  394. CHEUNG KS, Chen L, Chan EW, Seto WK, et al
    Nonsteroidal anti-inflammatory drugs but not aspirin are associated with a lower risk of post-colonoscopy colorectal cancer.
    Aliment Pharmacol Ther. 2020;51:899-908.
    PubMed     Abstract available


    April 2020
  395. AL-ANI A, Prentice R, Rentsch C, Johnson D, et al
    Review Article: Prevention, Diagnosis and Management of COVID-19 in the Inflammatory Bowel Disease Patient.
    Aliment Pharmacol Ther. 2020 Apr 29. doi: 10.1111/apt.15779.
    PubMed     Abstract available


  396. KREIJNE JE, de Vries AC, de Veer RC, Bouma G, et al
    Limited added value of laboratory monitoring in thiopurine maintenance monotherapy in inflammatory bowel disease patients.
    Aliment Pharmacol Ther. 2020 Apr 28. doi: 10.1111/apt.15734.
    PubMed     Abstract available


  397. SALAMEH R, Kirchgesner J, Allez M, Carbonnel F, et al
    Long-term outcome of patients with acute severe ulcerative colitis responding to intravenous steroids.
    Aliment Pharmacol Ther. 2020 Apr 28. doi: 10.1111/apt.15751.
    PubMed     Abstract available


  398. BIEMANS VBC, Savelkoul E, Gabriels RY, Simsek M, et al
    A comparative analysis of tioguanine versus low-dose thiopurines combined with allopurinol in inflammatory bowel disease patients.
    Aliment Pharmacol Ther. 2020 Apr 27. doi: 10.1111/apt.15730.
    PubMed     Abstract available


  399. DAUDE S, Remen T, Chateau T, Danese S, et al
    Comparative accuracy of ferritin, transferrin saturation and soluble transferrin receptor for the diagnosis of iron deficiency in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Apr 22. doi: 10.1111/apt.15739.
    PubMed     Abstract available


  400. LIU B, Wanders A, Wirdefeldt K, Sjolander A, et al
    Vagotomy and subsequent risk of inflammatory bowel disease: a nationwide register-based matched cohort study.
    Aliment Pharmacol Ther. 2020 Apr 22. doi: 10.1111/apt.15715.
    PubMed     Abstract available


  401. DULAI PS, Jairath V, Khanna R, Ma C, et al
    Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis.
    Aliment Pharmacol Ther. 2020 Apr 21. doi: 10.1111/apt.15726.
    PubMed     Abstract available


  402. KOCHHAR GS, Desai A, Syed A, Grover A, et al
    Risk of de-novo inflammatory bowel disease among obese patients treated with bariatric surgery or weight loss medications.
    Aliment Pharmacol Ther. 2020 Apr 21. doi: 10.1111/apt.15721.
    PubMed     Abstract available


  403. AMIOT A, Filippi J, Abitbol V, Cadiot G, et al
    Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study.
    Aliment Pharmacol Ther. 2020 Apr 14. doi: 10.1111/apt.15717.
    PubMed     Abstract available


  404. LEE HH, Bae JM, Lee BI, Lee KM, et al
    Pregnancy outcomes in women with inflammatory bowel disease: A 10-year nationwide population-based cohort study.
    Aliment Pharmacol Ther. 2020 Apr 7. doi: 10.1111/apt.15654.
    PubMed     Abstract available


  405. BIEMANS VBC, Sleutjes JAM, de Vries AC, Bodelier AGL, et al
    Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.
    Aliment Pharmacol Ther. 2020 Apr 1. doi: 10.1111/apt.15689.
    PubMed     Abstract available


  406. KING D, Reulen RC, Thomas T, Chandan JS, et al
    Changing patterns in the epidemiology and outcomes of inflammatory bowel disease in the United Kingdom: 2000-2018.
    Aliment Pharmacol Ther. 2020 Apr 1. doi: 10.1111/apt.15701.
    PubMed     Abstract available


  407. WILSON A, Peel C, Wang Q, Pananos AD, et al
    Letter: immunogenicity of infliximab-ready for routine prediction? Authors' reply.
    Aliment Pharmacol Ther. 2020;51:813-814.
    PubMed    


  408. AMIOT A
    Letter: immunogenicity of infliximab-ready for routine prediction?
    Aliment Pharmacol Ther. 2020;51:812.
    PubMed    


  409. VERSTOCKT B, Ferrante M
    Editorial: a clinical decision tool to identify patients who might benefit most from intensified dosing in the biological era-getting nearer?
    Aliment Pharmacol Ther. 2020;51:737-738.
    PubMed    


  410. DULAI PS
    Editorial: a clinical decision tool to identify patients who might benefit most from intensified dosing in the biological era-getting nearer? Authors' reply.
    Aliment Pharmacol Ther. 2020;51:738-739.
    PubMed    


  411. CHAPUIS-BIRON C, Bourrier A, Nachury M, Nancey S, et al
    Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients.
    Aliment Pharmacol Ther. 2020;51:719-727.
    PubMed     Abstract available


    March 2020
  412. LAURIOT DIT PREVOST C, Azahaf M, Nachury M, Branche J, et al
    Bowel damage and disability in Crohn's disease: a prospective study in a tertiary referral centre of the Lemann Index and Inflammatory Bowel Disease Disability Index.
    Aliment Pharmacol Ther. 2020 Mar 27. doi: 10.1111/apt.15681.
    PubMed     Abstract available


  413. HUPE M, Riviere P, Nancey S, Roblin X, et al
    Compared efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study.
    Aliment Pharmacol Ther. 2020 Mar 22. doi: 10.1111/apt.15680.
    PubMed     Abstract available


  414. RODRIGUEZ-LAGO I, Castro-Poceiro J, Fernandez-Clotet A, Mesonero F, et al
    Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Mar 17. doi: 10.1111/apt.15687.
    PubMed     Abstract available


  415. PIOVANI D, Danese S, Peyrin-Biroulet L, Nikolopoulos GK, et al
    Systematic review with meta-analysis: biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Mar 13. doi: 10.1111/apt.15692.
    PubMed     Abstract available


  416. MOURATIDOU N, Malmborg P, Sachs MC, Askling J, et al
    Adult height in patients with childhood-onset inflammatory bowel disease: a nationwide population-based cohort study.
    Aliment Pharmacol Ther. 2020 Mar 4. doi: 10.1111/apt.15667.
    PubMed     Abstract available


  417. BATTAT R
    Editorial: calcineurin inhibitors as a bridge to vedolizumab for severe ulcerative colitis.
    Aliment Pharmacol Ther. 2020;51:663-664.
    PubMed    


  418. WEI B, Wang J, Zhang Y, Zhao J, et al
    Letter: inflammatory bowel disease and risk of myocardial infarction.
    Aliment Pharmacol Ther. 2020;51:671-673.
    PubMed    


  419. SEBASTIAN S, Myers S
    Letter: infliximab induction regimens in steroid-refractory acute severe colitis-a propensity score analysis. Authors' reply.
    Aliment Pharmacol Ther. 2020;51:666-667.
    PubMed    


  420. TANDON P, Huang V
    Letter: increased risk of caesarean section for women with IBD-more questions than answers. Authors' reply.
    Aliment Pharmacol Ther. 2020;51:668-669.
    PubMed    


  421. SELINGER CP
    Letter: increased risk of caesarean section for women with IBD-more questions than answers.
    Aliment Pharmacol Ther. 2020;51:667-668.
    PubMed    


  422. AMIOT A
    Letter: new insights on tofacitinib dose de-escalation.
    Aliment Pharmacol Ther. 2020;51:578.
    PubMed    


  423. DULAI PS, Amiot A, Peyrin-Biroulet L, Jairath V, et al
    A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease.
    Aliment Pharmacol Ther. 2020;51:553-564.
    PubMed     Abstract available


  424. LEE S, Seow CH, Adhikari K, Metcalfe A, et al
    Pregnant women with IBD are more likely to be adherent to biologic therapies than other medications.
    Aliment Pharmacol Ther. 2020;51:544-552.
    PubMed     Abstract available


    February 2020
  425. D'AMICO F, Bonovas S, Danese S, Peyrin-Biroulet L, et al
    Review article: faecal calprotectin and histologic remission in ulcerative colitis.
    Aliment Pharmacol Ther. 2020 Feb 12. doi: 10.1111/apt.15662.
    PubMed     Abstract available


  426. PAI RK, Jairath V, Feagan BG
    Editorial: histologic normalisation in ulcerative colitis.
    Aliment Pharmacol Ther. 2020;51:399-401.
    PubMed    


  427. CUSHING KC, Ananthakrishnan AN
    Editorial: histologic normalisation in ulcerative colitis. Authors' reply.
    Aliment Pharmacol Ther. 2020;51:401.
    PubMed    


  428. MOCCIARO F, Scimeca D, Conte E, Bonaccorso A, et al
    Letter: the gap between guidelines and real clinical practice for dysplasia surveillance in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020;51:481-482.
    PubMed    


    January 2020
  429. SHAH ED, Coburn ES, Nayyar A, Lee KJ, et al
    Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System.
    Aliment Pharmacol Ther. 2020 Jan 28. doi: 10.1111/apt.15637.
    PubMed     Abstract available


  430. GIBSON DJ, Ward MG, Rentsch C, Friedman AB, et al
    Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Jan 21. doi: 10.1111/apt.15643.
    PubMed     Abstract available


  431. TANDON P, Govardhanam V, Leung K, Maxwell C, et al
    Systematic review with meta-analysis: risk of adverse pregnancy-related outcomes in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Jan 7. doi: 10.1111/apt.15587.
    PubMed     Abstract available


  432. KAYAL M, Ungaro R
    Letter: is measurement of faecal biomarkers helpful for the early diagnosis and prediction of pouchitis after proctocolectomy for ulcerative colitis? Authors' reply.
    Aliment Pharmacol Ther. 2020;51:190.
    PubMed    


  433. LAHARIE D, Riviere P
    Letter: should we intensify infliximab in acute severe ulcerative colitis?
    Aliment Pharmacol Ther. 2020;51:186-187.
    PubMed    


  434. SEBASTIAN S
    Letter: should we intensify infliximab in acute severe ulcerative colitis? Author's reply.
    Aliment Pharmacol Ther. 2020;51:188.
    PubMed    


  435. YAMAMOTO T, Shimoyama T, Kotze PG
    Letter: is measurement of faecal biomarkers helpful for the early diagnosis and prediction of pouchitis after proctocolectomy for ulcerative colitis?
    Aliment Pharmacol Ther. 2020;51:189-190.
    PubMed    


  436. PROBERT C
    Commentary: vitamin D supplementation in Crohn's disease.
    Aliment Pharmacol Ther. 2020;51:201-202.
    PubMed    


  437. TOWNSEND T, Subramanian S
    Editorial: endoscopic inflammation in ileoanal pouches-does it really matter?
    Aliment Pharmacol Ther. 2020;51:170-171.
    PubMed    


  438. BENSON-POPE SJ, Gearry RB
    Editorial: better outcomes for Crohn's disease-more than just the drugs?
    Aliment Pharmacol Ther. 2020;51:167-168.
    PubMed    


  439. HART A
    Commentary: safety of anti-TNF use in pregnancy.
    Aliment Pharmacol Ther. 2020;51:205-206.
    PubMed    


  440. KAYAL M, Ungaro R
    Editorial: endoscopic inflammation in ileoanal pouches-does it really matter? Authors' reply.
    Aliment Pharmacol Ther. 2020;51:172.
    PubMed    


  441. LUBER RP, Irving PM
    Editorial: establishing a joint approach to a common problem for gastroenterologists.
    Aliment Pharmacol Ther. 2020;51:306-307.
    PubMed    


  442. WINTER RW
    Editorial: effects of vedolizumab during pregnancy in the CONCEIVE study.
    Aliment Pharmacol Ther. 2020;51:307-308.
    PubMed    


  443. SHEN EX, Lord A, Doecke JD, Hanigan K, et al
    A validated risk stratification tool for detecting high-risk small bowel Crohn's disease.
    Aliment Pharmacol Ther. 2020;51:281-290.
    PubMed     Abstract available


  444. CARD T, Ungaro R, Bhayat F, Blake A, et al
    Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data.
    Aliment Pharmacol Ther. 2020;51:149-157.
    PubMed     Abstract available


  445. GENIN M, Fumery M, Occelli F, Savoye G, et al
    Fine-scale geographical distribution and ecological risk factors for Crohn's disease in France (2007-2014).
    Aliment Pharmacol Ther. 2020;51:139-148.
    PubMed     Abstract available


    December 2019
  446. OLLECH JE, Dwadasi S, Rai V, Peleg N, et al
    Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis.
    Aliment Pharmacol Ther. 2019 Dec 25. doi: 10.1111/apt.15616.
    PubMed     Abstract available


  447. DONG C, Metzger M, Holsbo E, Perduca V, et al
    Systematic review with meta-analysis: mortality in acute severe ulcerative colitis.
    Aliment Pharmacol Ther. 2019 Dec 10. doi: 10.1111/apt.15592.
    PubMed     Abstract available


    November 2019
  448. DULAI PS, Singh S, Jairath V, Ma C, et al
    Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis.
    Aliment Pharmacol Ther. 2019 Nov 22. doi: 10.1111/apt.15577.
    PubMed     Abstract available


  449. CUSHING KC, Tan W, Alpers DH, Deshpande V, et al
    Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission.
    Aliment Pharmacol Ther. 2019 Nov 7. doi: 10.1111/apt.15568.
    PubMed     Abstract available


  450. MOENS A, van der Woude CJ, Julsgaard M, Humblet E, et al
    Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study.
    Aliment Pharmacol Ther. 2019 Nov 6. doi: 10.1111/apt.15539.
    PubMed     Abstract available


  451. SOH H, Im JP, Han K, Park S, et al
    Crohn's disease and ulcerative colitis are associated with different lipid profile disorders: a nationwide population-based study.
    Aliment Pharmacol Ther. 2019 Nov 6. doi: 10.1111/apt.15562.
    PubMed     Abstract available


  452. MENON S, Bressler B
    Editorial: aminosalicylates and nephrotoxicity-an issue put to rest.
    Aliment Pharmacol Ther. 2019;50:1059.
    PubMed    


    October 2019
  453. SANDS BE, Armuzzi A, Marshall JK, Lindsay JO, et al
    Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open.
    Aliment Pharmacol Ther. 2019 Oct 29. doi: 10.1111/apt.15555.
    PubMed     Abstract available


  454. PIOVANI D, Danese S, Peyrin-Biroulet L, Bonovas S, et al
    Inflammatory bowel disease: estimates from the global burden of disease 2017 study.
    Aliment Pharmacol Ther. 2019 Oct 29. doi: 10.1111/apt.15542.
    PubMed     Abstract available


  455. WILSON A, Peel C, Wang Q, Pananos AD, et al
    HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Oct 25. doi: 10.1111/apt.15563.
    PubMed     Abstract available


  456. VARKAS G, Ribbens C, Louis E, Van den Bosch F, et al
    Expert consensus: practical algorithms for management of inflammatory bowel disease patients presenting with back pain or peripheral arthropathies.
    Aliment Pharmacol Ther. 2019 Oct 25. doi: 10.1111/apt.15519.
    PubMed     Abstract available


  457. GUBATAN J, Chou ND, Nielsen OH, Moss AC, et al
    Systematic review with meta-analysis: association of vitamin D status with clinical outcomes in adult patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Oct 24. doi: 10.1111/apt.15506.
    PubMed     Abstract available


  458. LUU M, Benzenine E, Barkun A, Doret M, et al
    Safety of first year vaccination in children born to mothers with inflammatory bowel disease and exposed in utero to anti-TNFalpha agents: a French nationwide population-based cohort.
    Aliment Pharmacol Ther. 2019 Oct 15. doi: 10.1111/apt.15504.
    PubMed     Abstract available


  459. SANDBORN WJ, Panes J, Sands BE, Reinisch W, et al
    Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.
    Aliment Pharmacol Ther. 2019 Oct 9. doi: 10.1111/apt.15514.
    PubMed     Abstract available


  460. SELINGER CP, Parkes GC, Bassi A, Limdi JK, et al
    Assessment of steroid use as a key performance indicator in inflammatory bowel disease-analysis of data from 2385 UK patients.
    Aliment Pharmacol Ther. 2019 Oct 8. doi: 10.1111/apt.15497.
    PubMed     Abstract available


  461. LUND K, Larsen MD, Knudsen T, Kjeldsen J, et al
    The impact of anti-TNFalpha therapy on colectomy rates and corticosteroid treatment among 3001 paediatric and adolescent patients with ulcerative colitis-a nationwide study from 1995 to 2015.
    Aliment Pharmacol Ther. 2019 Oct 3. doi: 10.1111/apt.15510.
    PubMed     Abstract available


  462. DOLINGER MT, Rolfes P, Phan BL, Dubinsky MC, et al
    Letter: tofacitinib use for biologic-refractory paediatric inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019;50:966-967.
    PubMed    


  463. LIN YS, Chen MJ, Lin WC, Wang YH, et al
    Letter: should we delay surgery, or stop anti-TNF therapy prior to elective surgical procedures in Crohn's disease patients receiving anti-TNF agents? Authors' reply.
    Aliment Pharmacol Ther. 2019;50:970-971.
    PubMed    


  464. YAMAMOTO T, Kotze PG
    Letter: should we delay surgery, or stop anti-TNF therapy prior to elective surgical procedures in Crohn's disease patients receiving anti-TNF agents?
    Aliment Pharmacol Ther. 2019;50:969-970.
    PubMed    


  465. WALL CL, Day AS
    Editorial: the reduction of faecal calprotectin during exclusive enteral nutrition is lost rapidly after food reintroduction.
    Aliment Pharmacol Ther. 2019;50:824-825.
    PubMed    


  466. ASHTON JJ, Beattie RM
    Letter: anti-TNF therapy and intestinal resections in Crohn's disease-are we just delaying the inevitable?
    Aliment Pharmacol Ther. 2019;50:842-843.
    PubMed    


  467. KORZENIK J, Larsen MD, Nielsen J, Kjeldsen J, et al
    Editorial: anti-TNF therapy-a double-edged sword? Authors' reply.
    Aliment Pharmacol Ther. 2019;50:823-824.
    PubMed    


  468. SCHREINER P, Biedermann L
    Editorial: anti-TNF therapy-a double-edged sword?
    Aliment Pharmacol Ther. 2019;50:822-823.
    PubMed    


    September 2019
  469. FRASCA JD, Cheifetz AS
    Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease-results from the ENEIDA registry.
    Aliment Pharmacol Ther. 2019;50:599-600.
    PubMed    


  470. IBORRA M, Beltran B, Nos P
    Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease-results from the ENEIDA registry. Authors' reply.
    Aliment Pharmacol Ther. 2019;50:600-601.
    PubMed    


  471. DETLIE TE, Jahnsen J
    Editorial: awareness and prevention of intravenous iron-induced hypophosphataemia. Authors' reply.
    Aliment Pharmacol Ther. 2019;50:610-611.
    PubMed    


  472. SEOW CH, Targownik LE
    Editorial: understanding sex and gender dimorphism in chronic diseases may improve outcomes.
    Aliment Pharmacol Ther. 2019;50:603-604.
    PubMed    


  473. MUSGROVE J, Wolf M
    Editorial: awareness and prevention of intravenous iron-induced hypophosphataemia.
    Aliment Pharmacol Ther. 2019;50:609-610.
    PubMed    


    August 2019
  474. LIN YS, Lin WC, Chen MJ, Wang YH, et al
    Letter: when to withhold anti-TNF agents prior to abdominal surgery in patients with Crohn's disease-the jury might still be out. Authors' reply.
    Aliment Pharmacol Ther. 2019;50:465-466.
    PubMed    


  475. GATES R, Fogel S, Nguyen VQ, Sorrentino D, et al
    Letter: when to withhold anti-TNF agents prior to abdominal surgery in patients with Crohn's disease-the jury might still be out.
    Aliment Pharmacol Ther. 2019;50:464-465.
    PubMed    


  476. ISTL A, Yang ML, Fleshner KA, Parker CE, et al
    Letter: pre-operative anti-TNF therapy in Crohn's disease is not associated with increased complications following elective surgery.
    Aliment Pharmacol Ther. 2019;50:467-468.
    PubMed    


  477. LIN YS, Chen MJ, Lin WC, Wang YH, et al
    Letter: pre-operative anti-TNF therapy in Crohn's disease is not associated with increased complications following elective surgery. Authors' reply.
    Aliment Pharmacol Ther. 2019;50:469-470.
    PubMed    


  478. PAUL S, Roblin X
    Letter: immunogenicity of anti-TNF in elderly IBD patients.
    Aliment Pharmacol Ther. 2019;50:336.
    PubMed    


  479. SINGH S, Jairath V
    Letter: immunogenicity of anti-TNF in elderly IBD patients-authors' reply.
    Aliment Pharmacol Ther. 2019;50:337.
    PubMed    


  480. GARBO GM, Renna S, Caputo V, Orlando E, et al
    Letter: psoriasiform eruption during vedolizumab therapy.
    Aliment Pharmacol Ther. 2019;50:342-343.
    PubMed    


    July 2019
  481. BANERJEE T, Gearry R
    Editorial: suicide and IBD-a call to action.
    Aliment Pharmacol Ther. 2019;50:105-106.
    PubMed    


  482. BRYANT RV, Costello SP
    Editorial: assessing histological disease activity in Crohn's disease-a call for standardisation of mucosal biopsy location.
    Aliment Pharmacol Ther. 2019;50:103-104.
    PubMed    


  483. MALHAM M, Jakobsen C, Hald M, Paerregaard A, et al
    Editorial: suicide and IBD-a call to action. Authors' reply.
    Aliment Pharmacol Ther. 2019;50:106-107.
    PubMed    


  484. VANDE CASTEELE N, Jairath V
    Editorial: assessing histological disease activity in Crohn's disease-a call for standardisation of mucosal biopsy location. Authors' reply.
    Aliment Pharmacol Ther. 2019;50:104-105.
    PubMed    


    June 2019
  485. MURRAY CDR
    Editorial: combination immunosuppressive therapy to treat Crohn's disease - ready for all age groups?
    Aliment Pharmacol Ther. 2019;49:1528.
    PubMed    


  486. SINGH S, Jairath V, Lw S, G Z, et al
    Editorial: combination immunosuppressive therapy to treat Crohn's disease - ready for all age groups? Authors' reply.
    Aliment Pharmacol Ther. 2019;49:1529.
    PubMed    


    May 2019
  487. IANIRO G, Eusebi LH, Black CJ, Gasbarrini A, et al
    Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome.
    Aliment Pharmacol Ther. 2019 May 28. doi: 10.1111/apt.15330.
    PubMed     Abstract available


  488. MURPHY B, O'Kane D, McCourt C
    Letter: paradoxical skin eruptions during anti-TNF-alpha treatment of Crohn's disease.
    Aliment Pharmacol Ther. 2019;49:1369-1370.
    PubMed    


    April 2019
  489. CHAN SSM
    Editorial: differences in sex-based incidence of inflammatory bowel diseases between Asia-Pacific and Western countries - are these due to differences in environment, access to healthcare, or pathophysiology?
    Aliment Pharmacol Ther. 2019;49:1098-1099.
    PubMed    


  490. VERSTOCKT B, Vermeire S, Ferrante M, Breynaert C, et al
    Editorial: biomarker predictors of non-response to TNFalpha antagonists - the quest continues. Authors' reply.
    Aliment Pharmacol Ther. 2019;49:1091-1092.
    PubMed    


  491. SHOUVAL DS, Ben-Horin S
    Editorial: biomarker predictors of non-response to TNFalpha antagonists-the quest continues.
    Aliment Pharmacol Ther. 2019;49:1089-1090.
    PubMed    


  492. LIN YS, Cheng SW, Wang YH, Chen KH, et al
    Systematic review with meta-analysis: risk of post-operative complications associated with pre-operative exposure to anti-tumour necrosis factor agents for Crohn's disease.
    Aliment Pharmacol Ther. 2019;49:966-977.
    PubMed     Abstract available


  493. CASTIGLIONE F, Imperatore N, Testa A, De Palma GD, et al
    One-year clinical outcomes with biologics in Crohn's disease: transmural healing compared with mucosal or no healing.
    Aliment Pharmacol Ther. 2019;49:1026-1039.
    PubMed     Abstract available


  494. CATT H, Hughes D, Kirkham JJ, Bodger K, et al
    Systematic review: outcomes and adverse events from randomised trials in Crohn's disease.
    Aliment Pharmacol Ther. 2019;49:978-996.
    PubMed     Abstract available


  495. ADAR T, Faleck D, Sasidharan S, Cushing K, et al
    Comparative safety and effectiveness of tumor necrosis factor alpha antagonists and vedolizumab in elderly IBD patients: a multicentre study.
    Aliment Pharmacol Ther. 2019;49:873-879.
    PubMed     Abstract available


  496. SHAH SC, Khalili H, Chen CY, Ahn HS, et al
    Sex-based differences in the incidence of inflammatory bowel diseases-pooled analysis of population-based studies from the Asia-Pacific region.
    Aliment Pharmacol Ther. 2019;49:904-911.
    PubMed     Abstract available


    March 2019
  497. VERSTOCKT B, Verstockt S, Creyns B, Tops S, et al
    Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease.
    Aliment Pharmacol Ther. 2019;49:572-581.
    PubMed     Abstract available


    February 2019
  498. DING R, Xu J, He Z, Chen Y, et al
    Letter: different risks of venous thromboembolism in subsets of patients with inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2019;49:345-346.
    PubMed    


  499. CHU TPC, Grainge MJ, Card TR
    Letter: different risks of venous thromboembolism in subsets of patients with inflammatory bowel diseases - authors' reply.
    Aliment Pharmacol Ther. 2019;49:346.
    PubMed    


  500. PANES J, D'Haens GR, Higgins PDR, Mele L, et al
    Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study.
    Aliment Pharmacol Ther. 2019;49:265-276.
    PubMed     Abstract available


  501. LAI CY, Sung J, Cheng F, Tang W, et al
    Systematic review with meta-analysis: review of donor features, procedures and outcomes in 168 clinical studies of faecal microbiota transplantation.
    Aliment Pharmacol Ther. 2019;49:354-363.
    PubMed     Abstract available


    January 2019
  502. MACALUSO FS, Cappello M, Giuffrida E, Fries W, et al
    Letter: SPOSIB SB2-a Sicilian prospective observational study of IBD patients treated with infliximab biosimilar SB2.
    Aliment Pharmacol Ther. 2019;49:234-236.
    PubMed    


  503. LEMBERG DA, Day AS
    Editorial: predicting response to treatment in children with Crohn's disease.
    Aliment Pharmacol Ther. 2019;49:230-231.
    PubMed    


  504. HYAMS JS, Dubinsky M, Rosh J, Ruemmele FM, et al
    The effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in paediatric patients with Crohn's disease: a post hoc analysis.
    Aliment Pharmacol Ther. 2019;49:155-164.
    PubMed     Abstract available


  505. HALMOS EP, Mack A, Gibson PR
    Review article: emulsifiers in the food supply and implications for gastrointestinal disease.
    Aliment Pharmacol Ther. 2019;49:41-50.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: